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ABSTRACT OF THE DISSERTATION
RNA-Seq Reveals Transcriptomic Program Associated with Stemness in Taxane
Resistant Prostate Cancer
by
Christina K. Cajigas-Du Ross
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, August 2018
Dr. Carlos A. Casiano, Chairperson
There is no cure for advanced prostate cancer (PCa), and taxane chemotherapy is
the only treatment option once other therapies have failed. However, this is problematic
since all patients eventually develop chemoresistance. Emerging treatments for advanced
PCa have shown promise at the benchside, but clinical trials have not resulted in newly
approved drugs due in part to redundant survival pathways utilized by prostate tumor
cells to maintain therapy-resistance. Using RNAsequencing—an innovative approach for
quantifying gene expression changes—this dissertation sought to elucidate
chemoresistance-associated molecular pathways as a catalyst to develop new therapeutic
targets. Results revealed a differential upregulation of stemness-associated genes in PCa
cells selected for chemoresistance. In addition, chemoresistant cells formed robust stem
cell prostaspheres compared to chemosensitive cells, and expressed other markers of
cancer stem cells. Overall, these findings support the hypothesis that PCa
chemoresistance is driven by cancer stem cells.

xv

CHAPTER ONE
INTRODUCTION
Prostate Cancer Background and Available Therapies
Prostate cancer (PCa) is currently the most commonly diagnosed cancer and the
second leading cause of cancer deaths in American men with 164,690 estimated new
cases and 29,430 deaths projected in 2018 [1]. PCa also exhibits a striking racial
disparity, as African American men are 1.4 times greater risk of being diagnosed and 2.5
times more likely to die of this disease compared to Non-Hispanic white males [2, 3]. In
addition, African American men are diagnosed with PCa at an earlier age and with a
more advanced stage compared with Non-Hispanic white men, which may partially
explain the significant mortality disparity seen in this population. Although PCa
disproportionately and aggressively affects African American men [2, 3], this group is
still underrepresented in potentially life-saving clinical trials. Furthermore, this
underrepresentation could affect the development of newer cancer treatments since
specific molecular targets might be more sensitive to slight differences in genetic
variation seen across different ethnic or racial backgrounds [4]. The likelihood of being
diagnosed with PCa increases with age; this is problematic considering the increasing
aging male population. Therefore, the aging male population and the complexity of
addressing the mortality disparity make developing new effective treatments for PCa
crucial for tackling this public health dilemma and the subsequent fiscal burden that is
expected over the next few decades [2-5].
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PCa Screening and Diagnosis
PCa is diagnosed in patients through a combination of screening procedures.
Digital rectal examination (DRE) is typically performed by a primary care physician. The
DRE allows the physician to detect abnormal size or hard nodules of the prostate. The
prostate-specific antigen (PSA) blood test is a screening tool used in combination with
DRE. PSA is synthesized in the prostate and the concentration in the blood increases with
PCa [6]. Circulating serum PSA is considered high or abnormal when detected above 4
ng/ml [7]. While elevated levels of PSA are not always indicative of PCa, it often
requires follow-up monitoring or screening, including biopsy.
Once a tissue sample of the prostate is removed for biopsy, a pathologist is able to
assign a Gleason score, which is used by the physician to determine aggressiveness and
stage of the cancer. The higher the Gleason score, the more likely the PCa will spread
rapidly and be aggressive [8]. Gleason scores range from a value of 1-5 with number 1
representing small uniform glands and number 3 representing moderately differentiated
cells with infiltration of cells from glands at the margins. A score higher than 3 represents
poorly differentiated and anaplastic cells with irregular masses of neoplastic cells and
lack of glands [8]. PCa biopsies typically reveal phenotypic heterogeneity of histological
subtypes found in the prostate adenocarcinoma cells. They include luminal secretory,
neuroendocrine, basal, and luminal epithelial cells [9]. As a result of this heterogeneity,
the pathologist may identify the two most common grades and add them to determine the
combined Gleason score, which can range from 6-10. A PCa diagnosis typically occurs
when the combined Gleason score is at least 6, with scores above 7 indicative of
aggressive PCa.
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The heterogeneity of this malignancy makes it an enormous challenge to develop
therapeutic strategies that will be effective for all PCa patients. At early stages, treatment
options including radical prostatectomy and radiation can be curative. But treatment
options for advanced-stage diagnosis including androgen deprivation therapy (ADT) and
taxane chemotherapy are not as effective since the disease has progressed and is
phenotypically aggressive (Figure 1). Therefore, a diagnosis with advanced PCa is
problematic for the patient given the lack of curative options.
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PCa progression and treatment options
Localized PCa

Biochemical
Recurrence

Metastatic
castration-resistant
PCa (mCRPC)

Chemoresistant
mCRPC

• Watchful Waiting
• Radical
prostatectomy
• Radiation
• Proton therapy

• Primary androgen
deprivation
therapy (ADT)

• Secondary ADT
(Enzalutamide)
• Docetaxel (chemotherapy)
+ prednisone

• Cabazitaxel
(chemotherapy)
+ prednisone

Terminal

• Palliative care
• No current
effective
treatments

Figure 1. Prostate Progression and Treatment Options. Stages and treatment options
available for PCa. PCa is curable if treated while localized in the prostate. Unfortunately,
once tumor cells migrate out of the organ, the disease is no longer curable and treatments
are only meant to delay disease progression. ADT is the main treatment option at any
state of PCa, especially following biochemical recurrence. Metastatic castration resistant
PCa is treated with taxane chemotherapy and secondary ADT. Once a patient is terminal
and no longer responding to chemotherapy, palliative care is the only treatment option
available.
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Androgen Receptor and ADT
Men initially diagnosed with PCa are given several treatment options including
prostatectomy (prostate removal) or radiation to destroy cancerous cells still remaining in
the prostate capsule after removal. Many patients, however, are not cured by these
treatments and their cancer returns [10]. This is typically detected by an increased in PSA
levels, known as biochemical recurrence. For men diagnosed with advanced PCa,
treatment with curative intent is no longer an option, and ADT remains the main
therapeutic modality [10, 11]; this is because prostate tumor growth is initially dependent
on androgens. Testosterone, secreted primarily by the testes, is the main circulating
androgen that is secreted in the blood. When testosterone enters the prostate cells, 90% is
converted to a more active hormone dihydrotestosterone (DHT) by the enzyme 5-alphareductase. DHT has a 5-fold higher affinity for androgen receptor (AR) than testosterone
[10, 11]. AR is a nuclear receptor comprised of an amino-terminal activating domain, a
carboxy-terminal ligand-binding domain, and a DNA-binding domain. In its basal state,
AR is bound to heat-shock proteins in a conformation that prevents DNA binding.
Androgen binding to AR induces a conformational change that causes dissocation from
binding proteins and leads to the formation of AR homodimer complexes that can bind to
androgen response elements in the promoter regions of target genes that contribute to
cancer progression and aggressiveness [10].
ADT includes any treatment that suppresses androgen activity by decreasing
androgen production through medical castration or by using anti-androgens to block AR
signaling. The benefit of ADT in PCa treatment is the upregulation of pro-apoptotic
genes that are normally repressed by AR activation [12], leading to a temporary reduction

5

in tumor aggressiveness. Common anti-androgens include cyproterone acetate, flutamide,
nilutamide, and bicalutamide, all of which block androgens from binding to AR receptor
(antagonists). Medical ADT is most commonly used in combination with long-acting
gonadotrophin-releasing hormone (GnRH) agonists that are equally effective in reducing
testosterone levels as removal of the testes with less detrimental effects. In addition,
prostate tumors express GnRH receptors and GnRH analogs are shown preclinically to
have antitumor activity [12].

Castration-Resistant PCa
Despite the imporant clinical benefits seen with ADT including improved
survival, less morbidity, and better quality of life, it is not curative. This is because, after
an average of 2-3 years of ADT, PCa cells reactivate AR signaling and continue to
proliferate despite extremely low levels of circulating testosterone, a stage called
castration-resistant prostate cancer (CRPC) [11, 12]. Cells bypass AR targeting through a
variety of mechanisms including AR amplification and mutation, co-activator and corepressor modifications, aberrant activation/post-translational modification, altered
steroidogenesis, the presence of AR splice variants, and as discussed below,
glucocorticoid receptor bypass [11].
AR amplification and increased AR sensitivity are both utilized by PCa cells to
bypass androgen ablation therapy, and both mechanisms are dependent on androgens
being present. By amplifying expression of the AR gene, cells have an increased number
of AR resulting in increased AR expression and enhanced ligand-occupied receptor
content despite low androgen concentrations [11, 12]. This is most likely achieved
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through clonal selection of cells that proliferate despite low levels of circulating
androgens as evidenced by the fact that tumors were found to have this AR amplification
only after androgen ablation [10]. Increased AR sensitvity is another mechanism that
results in AR signaling activation despite low androgens. This pathway results in high
AR expression, increased stability and enhanced nuclear localization of AR in tumor cells
[10]. Finally, PCa cells can also increase local production of androgens by elevating 5alpha-reductatse activity thereby increasing the rate of conversion of testosterone to DHT
[10].
PCa cells can also undergo AR point mutations causing an increase in AR activity
in response to low circulating androgens. These mutations can also broaden the ligand
pool to which AR responds, causing PCa cells to circumvent normal growth regulation by
androgens. These mutations lead to aberrant activation of the androgen signaling axis by
decreasing the specifity of ligand binding, and allow the ability for non-androgenic
steroids and androgen antagonists to bind to AR and activate transcription of AR target
genes [10]. Another pathway by which AR can be activated includes mutations to the
many co-activators and co-repressors that function normally to regulate AR activation.
Mutations to the co-regulator complexes can improve androgen-stimulated AR activation
and also lead to disease progression [10, 11].
Metastatic CRPC (mCRPC) is a lethal stage of PCa that is marked by recurrence
of elevated PSA and progression of metastatic lesions [10]. Since 2004, the standard firstline chemotherapeutic agent for mCRPC has been the taxane drug docetaxel (DTX), a
microtubule-stabilizing agent that moderately increases overall survival [13, 14].
Eventually, however, chemoresistance occurs in all DTX-treated patients resulting in
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continued disease progression ultimately leading to patient death [15]. Research focusing
on the mechanisms of DTX-resistance have led to the development of new treatment
options for mCRPC to target those pathways implicated. They include the nextgeneration AR-targeting agents abiraterone acetate and enzalutamide, therapeutic
vaccines, and the second generation taxane cabazitaxel [15, 16]. Abiraterone acetate is an
inhibitor of cytochrome P-450 17A1, the enzyme crucial for androgen biosynthesis.
Unlike GnRH analogs, abiraterone acetate reduces androgen synthesis at the adrenal,
prostate, and intratumoral sites. Enzalutamide is a more potent AR signaing inhibitor
compared to conventional anti-androgens because it inhibits AR nuclear translocation,
DNA binding, and co-activator recruitment [10]. Both abiraterone acetate and
enzalutaminde are administered sequentially or in combination wth DTX and
unfortunately lead to a modest median of 4-5 month improvement in survival [10, 12]. In
2012, the FDA expanded approval for abiraterone acetate use in patients who have not
yet received chemotherapy [12].

Glucocorticoid Receptor “Take-Over” Pathway
Despite the initial success reported with abiraterone and enzalutamide treatment,
after an average of 6-12 months, response is limited due to acquired resistance. Recent
work has highlighted another mechanism by which patients become resistant to antiandrogens, specifically enzalutamide [11, 17]. This pathway involves an increased
expression of glucocorticoid receptor (GR) and a bypass of AR-target genes with
evidence showing that GR can bind to over half of all AR binding sites [11]. GRs are
nuclear receptors very similar in structure to AR. In addition, glucocorticoids initially
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have a suppressive effect on PCa and are often given in combination with early CRPC
treatments [11]. Because the DNA binding domain of the glucocorticoid receptor is
similar to that of AR, its upregulation in patients treated with chemotherapy or ADT may
contribute to enzalutamide resistance [11]. GR expression was found to be upregulated in
these resistant tumors and implicated in substituting AR to activate a similar but
distinguishable set of genes that was determined to be necessary for the maintenance of
enzalutamide resistance [17]. These findings were critical in establishing a key
mechanism detailing an escape from AR blockade through the selection of cells that are
able to drive the expression of AR target genes via an alternative nuclear receptor [17].

AR Splice Variants Contribute to CRPC
There is a significant subset of patients receiving abiraterone acetate or
enzalutamide who do not respond to either treatment; this is called innate or primary
resistance. In addition, the vast majority of patients who do initially respond to these two
drugs will eventually develop acquired or secondary resistance. Understanding the
mechanisms involved in primary and secondary resistance is an area of recent focus, with
the activity of AR splice variants (ARVs) being implicated as a putative resistance
mechanism in CRPC [18]. ARVs are truncated versions of wild type AR that are
considered constitutively active. The role of ARV expression in clinical CRPC is
currently being established, with some groups showing that ARVs are associated with
poorer prognosis, and others reporting higher levels of ARV expression in CRPC bone
metastasis compared to hormone-sensitive PCa bone metastasis [11].
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There are over 20 described ARVs, with the most abundant being the ARV7.
ARV7 is clinically relevant, with detection in human clinical samples from patients with
CRPC [18]. Secondly, ARV7 is also a constitutively active variant that is capable of
stimulating transcription of AR genes in the absence of androgens and cannot be
inhibited in vitro or in vivo by drugs that target the AR ligand-binding domain [18].
Thirdly, ARV7’s relevance is supported by the fact that its expression is increased 20fold in CRPC tissues compared to hormone-sensitive tissues [18]. Therefore, there is
evidence for the use of ARV7 as a prognostic marker to either determine poor outcomes
in patients with CRPC or as a treatment-selection marker that can provide additional
prognostic information[18]. Before the overall contribution of ARV7 can be determined,
however, further work needs to be done including testing the clinical utility of ARV7 in
the context of other therapies (i.e. taxanes), validating assay performance, and validating
the clinical relevance of ARV7 status in predicting response/resistance to treatment in a
context-specific manner [11, 18].

Taxane Chemotherapy
DTX chemotherapy is the current standard of care for patients diagnosed with
CRPC, based on the SWOG 9916 and TAX327 clinical trials, which demonstrated a 3month survival advantage of DTX over mitoxantrone [11, 14, 19]. DTX is an anti-mitotic
chemotherapeutic agent that inhibits mitosis by stabilizing the microtubules and binding
to the " subunit, preventing depolymerization and resulting in cell death. With the
approval of abiraterone acetate and enzalutamide, DTX is often not the first line therapy
of choice [11]. The CHAARTED trial compared DTX and ADT vs. ADT alone in
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hormone-naïve Pca patients. This clinical trial demonstrated that DTX can be used as an
initial treatment option for hormone-naïve patients since DTX in combination with ADT
resulted in a 17-month survival advantage over ADT alone in patients with visceral
metastases [11, 20]. The STAMPEDE trial showed similar results to CHAARTED with
DTX in combination with ADT resulting in a 10-month survial benefit over ADT alone
in men with high-risk locally advanced or metastatic PCa [11, 21]. Despite its
effectiveness, all DTX-treated patients eventually develop resistance, and there are
numerous mechanisms implicated in this acquired resistance [11, 15].
The taxane drug cabazitaxel (CTX) is a chemotherapeutic agent approved by the
Food and Drug Administration (FDA) for use in patients with mCRPC who failed DTX
chemotherapy. CTX was developed to have poor affinity for ABCB1 due to the role of
this efflux pump in mediating DTX resistance [15, 22]. CTX was found to have a 2.4month survival benefit compared to mitoxantrone in patients with mCRPC who
progressed with DTX treatment [11, 23]. As with DTX, patients treated with CTX also
develop resistance and face disease progression [11, 15, 24] Therefore, there is a need for
novel combinatorial therapies aimed at killing the tumors and circumventing resistance.

Mechanisms of Taxane Chemoresistance
Multidrug transporters
The mechanisms contributing to DTX-resistance are well-studied but poorly
understood as evidenced by the fact that therapies aimed at targeting these pathways have
failed clinically [11]. DTX-resistance has been linked to the activity of multidrug
transporters that act as efflux pumps to reduce the intracellular concentrations of
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chemotherapeutic agents [24, 25]. Multidrug transporters are membrane proteins
belonging to the ATP-binding cassette (ABC) family of transporters. The most notable
are ABCB1, MDR protein 1 (MRP1) or ABCC1, and breast cancer resistance protein
(BCRP) or ABCG2 [11], all of which are associated with drug resistance [24].
ABCB1 is weakly expressed in normal prostate but its expression increases as
disease stage and tumor grade increase. It is also highly expressed in DTX-resistant PCa
cells [24-26] and primary cancer cell cultures [24]. MRP1/ABCC1 and BCRP/ABCG2
are both associated with a multi-drug resistant phenotype. Unlike ABCB1, ABCC1 is
more readily expressed in DTX-sensitive PCa cell lines, but like ABCB1 its expression
also correlates with advanced PCa and high Gleason score [24, 27]. ABCG2 has been
shown to have a possible role in PCa progression with expression correlating with worse
patient survival. In addition, phosphorylation of ABCG2 by the serine/threonine kinase
Pim-1 mediates DTX-resistance in PCa cell lines [28]. Interestingly, ABCG2 is a well
established universal and PCa stem cell marker [29], and its expression has been
implicated in the innate chemoresistance observed in stem cells [24]. Preclinical data
determining the role of multidrug transporters in chemotherapy resistance led to the
development of CTX, designed to have low affinity for ABCB1 efflux [15, 24].

Tubulin Isoforms
Another mechanim assocated with DTX-resistance is the upregulation of class III
"-tubulin isoforms which are common in DTX-resistant cancer cell lines and result in
less stable microtubules [24]. Elevated "III-tubulin is correlated with poor response to
tubulin-targeting agents and with poor prognosis in many human malignancies. In
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addition, targeting of this isoform restores DTX sensitivity [30]. DTX-resistant cells have
elevated expression of "III-tubulin, which is clinically associated with disease
progression, tumor aggressiveness, and poor response to taxane therapy [30, 31].
Although this isoform has been well-characterized in DTX-resistant breast cancer, this
mechanism of resistance has yet to be confirmed in PCa due to lack of metastatic biopsy
samples of taxane-resistant tumors to specifically examine tubulin alterations. Further
studies are required to determine the impact of these modifications in clinical decisionmaking [31].

Survival Pathways and Inflammatory Cytokines
STAT-1 and STAT-3
The binding of DTX to "-tubulin induces a stress response that activates multiple
survival pathways inducing c-JNK, STAT-1 and STAT-3, and NF-!B. STAT (signal
transducer and activator of transcription) proteins are transcription factors that regulate
gene expression and influence cell growth, differentiation, proliferation, and apoptosis
[32]. When PC3 and DU145 mCRPC cells become resistant to DTX, STAT1-dependent
clusterin (CLU) expression is upregulated [33]. CLU is an anti-apoptotic protein that is
associated with PCa progression and chemoresistance [34]. STAT-3 expression is also
implicated in DTX-resistance through the serine-threonine kinase PIM1, contributing to
cell survival [35].

NF-!B
Inflammation has long been established as a major driver in PCa carcinogenesis
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and progression [36], and its role in DTX-resistance has been well-studied with several
groups demonstrating inflammatory cytokine upregulation in mCRPC patients treated
with DTX. NF-!B is found in the cytoplasm and is inhibited by I!B-#. When I!B
kinases are stimulated, I!B-# is degraded and NF-!B is able to translocate to the nucleus
and activate transcription of a wide array of genes that code for angiogenic factors, cell
adhesion molecules, anti-apoptotic factors, and cytokines [32, 37]. These genes are
thereby able to contribute to cell survival, invasion, metastasis, and chemoresistance [32].

IL-6 and IL-8 Signaling
Among the many targets of NF-!B are the genes that encode for Interleukin 6 (IL6) and Interleukin 8 (IL-8), two cytokines that stimulate PCa cell growth in an autocrine
and paracrine manner and are involved in the development and progression of the disease
[38-41]. Androgen-independent PC3 and DU145 PCa cells have elevated IL-6 and IL-8
production in conditioned media due to NF-!B activity. This same observation does not
occur in androgen-sensitive LNCaP PCa cells [38, 40]. PC3 and DU145 cells have higher
NF-!B activity and secreted more IL-6, making them more resistant to DTX compared to
LNCaP cells [42]. Pharmacological inhibition of NF-!B reduced IL-6 levels and
increased the cytotoxic effects of DTX in PC3 and DU145 cells but not LNCaP cells
[42]. This finding is supported clinically by a significant association in mCRPC PCa
patients between high serum and tumor expression levels of IL-6 and decreased response
to DTX treatment [37, 42]. High IL-6 and IL-8 production enhances proliferation and
inhibits apoptosis in PC3 and DU145 cells [38, 40]. Through the JAK/STAT pathways,
IL-6 and IL-8 are effectors of NF-!B activity in DTX-resistance [38, 40].
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CCL2
Chemokines, which function to induce chemotaxis in neighboring cells, have also
been implicated in DTX-resistance. Most notable is the chemokine ligand 2 (CCL2),
which is expressed in PCa cell lines and primary tumors and is correlated with malignant
potential [43, 44]. CCL2 expression in mCRPC cell lines is increased by DTX treatment
through the activation of JNK signaling resulting from DTX binding to microtubules
[45]. In addition, CCL2 can act in an autocrine manner to promote cell survival and
resistance to DTX through stimulation of Erk/MAP kinase and PI3K/AKT signaling
pathways [46, 47].

Chaperone Proteins
Heat Shock Proteins
Chaperone proteins have long been implicated in DTX-resistance, with heat shock
proteins and CLU being the most notable and extensively studied [32]. Heat Shock
Protein 27 (HSP27) and HSP90 are overexpressed in mCRPC cells and their expression
increases as cells become DTX-resistant [48, 49]. In addition, targeting of these proteins
in cellular models resulted in DTX resensitization [49, 50]. Unfortunately, however,
clinical trials targeting HSP90 have yet to improve overall survival [32]. Clinical studies
with HSP27 using the second generation antisense drug OGX-427 resulted in a decrease
in circulating tumor cells in mCRPC patients [49]. Results from Phase I clinical trials in
mCRPC patients using OGX-42 in combination with DTX have yet to be reported.
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Clusterin
CLU, a chaperone protein, is upregulated in DTX-resistant PCa cells and is
considered a key protein in mediating DTX-resistance in PCa [34]. CLU exists in two
isoforms resulting from two distinct transcriptional start sites. They include a truncated
nuclear form (nCLU) that promotes CRPC cell death [51], and a secreted form (sCLU)
that prevents cell death [52]. nCLU and sCLU are not produced simultaneously, and a
shift from nCLU to sCLU production occurs during PCa progression [53]. Therefore,
nCLU expression is not detected in prostate tumor cells and sCLU is overexpressed in
DTX-resistant cells, with elevated expression levels correlating with DTX resistance
[54]. sCLU in vitro knockdown with antisense oligonucleotide increases the sensitvity of
resistant PCa cells [55].
As previously mentioned, sCLU expression is induced by DTX through STAT-1
activation in PC3 and DU145 cells. AKT inhibition suppressed CLU expression in DTXresistant CRPC cells and resensitized them to DTX, showing that CLU expression is
dependent on AKT activation of STAT-1 [56]. sCLU confers its anti-apoptotic effects in
the cytoplasm of the cell by binding and stabilizing the Ku70-Bax complex preventing
the release of Bax to the mitochondria to initiate cytochrome c release and thereby
preventing caspase-9 and -3 dependent apoptosis [34, 57].
CLU is also regulated by transforming growth factor "1 (TGF-"1) [58]. TGF-"1
is in turn upregulated by the transcription factors YB-1 and Twist 1 [58]. Through this
upregulation, CLU contributes to epithelial-mesenchymal transition (EMT) and
metastasis of PCa cells [58]. CLU reduction reduced TGF-"1induction of N-cadherin and
fibronection, both markers of EMT, thereby inhibiting the migratory and invasive
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properties of TGF-"1 [58]. Targeting of CLU in an in vivo model also suppressed
metastasis. These findings indicate that CLU is an important mediator of TGF-"1induced EMT, and CLU may be a promising target for reducing cancer metastasis [58].

AR Splice Variants in the Context of Taxane Chemoresistance
PCa is fundamentally AR-driven especially in the context of disease etiology and
progression. Because the intraprostatic response of PCa cells to androgens depends on the
expression and sensitivity of ARs, ADT has been a mainstay of PCa treatment and
typically precedes taxane chemotherapy. As mentioned above, constitutively active
ARVs have been shown to be overexpressed in mCRPC and confer resistance to ADT by
inhibiting the nuclear translocation of the androgen-AR complex [59-62]. More recently,
there has been a shift in focus to the role of AR in DTX-resistance in mCRPC patients
with AR mutations. An initial study suggested that the presence of AR splice variants
may affect sensitivity to taxane treatment and that tumors predominantly expressing
ARV7 would likely be resistant to DTX [63].
Since this initial report, a separate group has coordinated a replication study and
their results refute the initial findings regarding ARV7 and DTX-resistance [64]. In
addition, a separate group found that detection of ARV7 in circulating tumor cells of
mCRPC patients was not associated with taxane-resistance, negating the clinical
significance of ARV7 in patients receiving DTX [18]. Considering the inconsistency
reported in the literature regarding AR-DTX interactions, studies exploring DTXresistance using cellular models must take into account the AR status of cell lines used to
determine the most clinically relevant scenario for the question being addressed.
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LEDGF/p75 Promotes DTX-Resistance
The Lens Epithelial Derived Growth Factor protein of 75 kDa (LEDGF/p75) is
activated during cellular response to stress. It is a transcription co-activator with
oncogenic function [65, 66] that specifically promotes cellular survival against
environmental stressors such as oxidative stress, radiation, heat, serum starvation, and
cytotoxic drugs [26, 65-70]. LEDGF/p75 has been shown to have a role in PCa and other
cancers, contributing to resistance to various cytotoxic drugs, including DTX [26, 68, 70,
71]. DTX-resistant PCa cell lines upregulate transcript and protein expression of
LEDGF/75 compared to DTX-sensitive cells [26, 48, 71]. Our group has also
demonstrated that siRNA-mediated knockdown of LEDGF/p75 is able to partially
resensitize DTX-resistant cells to DTX therapy [26].

Epithelial to Mesemchymal Transition
EMT occurs when there is a breakdown of cell-to-cell-to-extracellular matrix
adherence to the epithelial lining [72], a process that facilitates cancer metastasis. Ecadherin, a major component of epithelial adherence junction, functions to control EMT
[72, 73]. Loss of E-cadherin is the hallmark step that signals the start of EMT [72].
Crucial mesenchymal markers include vimentin, N-cadherin, and E-cadherin
transcriptional repressors including SNAI1 (Snail), SNAI2 (slug), TWIST1(Twist),
ZEB1, and ZEB2; all of which contribute to enhanced cell mobility [72, 73].
In our studies, Snail, Twist, vimentin, and N-cadherin were found elevated in the
DTX-resistant PC3-DR and DU145-DR cells. Snail is a zinc-finger protein that binds to
the E-cadherin promoter [72]. Snail is upregulated during enzalutamide resistance and is
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highly expressed in metastatic PCa [72]. Snail’s role in facilitating metastasis involves
the downregulation of tight junction proteins including zona occludin 1 [72]. Twist is a
protein that plays critical roles during tumorigenesis also through the regulation of Ecadherein expression [73]. Twist’s expression is significantly correlated with Gleason
score and metastasis. Twist also functions to regulate N-cadherin expression by inducing
transcriptional activation [73, 74]. Slug, another transcription factor, is regulated by AR
signaling and contributes to the develepment of CRPC during ADT [73]. This evidence
suggest that EMT contributes to drug resistance in PCa.
The link between EMT and cancer stem cells (CSCs) in contributing to drug
resistance in CRPC has recently been explored in various cancer types [73-76]. What is
emerging from these studies is the hypothesis that characteristics of EMT are closely
associated with signatures of CSCs, leading to the drug resistant phenotype. Evidence for
this has been observed in breast and pancreatic cancer, where TGF", a potent EMT
inducer, stimulated a marked increase of cells with a CSC phenotype and marker
expression [73]. In addition, a study in breast cancer demonstrated that upregulation of
Zeb1, an EMT regulator, was sufficient to switch cells from a non-cancer stem cell
phenotype to a CSC status [76]. This link between EMT markers and CSC-like
phenotype in DTX-resistance in CRPC is explored in this dissertation.

Cancer Stem Cells
PCa resistance to chemotherapy, the primary cause of treatment failure, is driven
by the survival of subpopulations of prostate tumor cells that eventually contribute to
aggressive disease progression, characterized by metastasis to the bone and vital organs
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[77]. In addition, PCa tumors are highly heterogenous, with many areas containing
genetically distinct clones [78], a characteristic that also contributes to therapy resistance
and tumor relapse [77]. An emerging explanation for both the cellular heterogeneity and
treatment resistance in PCa and other solid tumors is the CSC hypothesis, which states
that solid tumors are organized heirarchically with only a small subset of cells capable of
tumor-initiating and tumor-propagating capacity [77, 79].
CSCs are defined by their capacity for self-renewal, potential to differentiate into
any cell-type within a tumor, and proliferative capacity to drive the establishment of a
tumor. The ability to expand or repopulate a bulk tumor is the result of aggressive
metastatic activity, and increased resistance to chemotherapy and radiotherapy [79]. The
CSC theory establishes that stem-like cells maintain the tumor population. Recent studies
suggest that cancer cells can de-differentiate into CSCs under certain tumor
microenvironmental conditions [79, 80]. This phenomenon is referred to as plasticity [79,
80].
Chemotherapeutic drugs, like DTX, have cytotoxic effects on the bulk tumor, but
due to the presence of CSCs, these effects are temporary since this small cell population
employs multiple redundant mechanisms that facilitate cell survival. In addition, the nonproliferative state of CSCs allows them to exist as cellular reserves facilitating an
environment where a small population of cells can persist after anti-proliferative
treatments repopulate the tumor and/or metastasize [77]. Recently the emerging role of
CSCs in the acquisition of PCa chemoresistance has been explored and partially
characterized [75, 77, 81, 82]. CSCs employ many of the same resistance mechanisms
previously mentioned but at an enhanced level, including increased activity of drug-
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efflux pumps, heightened DNA repair efficiency, and increased detoxification enzyme
expression; but unlike other cells, they employ quiescence [83]. Quiescence is of
particular concern when considering that the mechanism-of-action of many cytotoxic
drugs depends on the propensity of cancerous cells to be metabolically active and rapidly
dividing.
CSCs are typically identified based on the presence and/or absence of several cell
surface markers, the combination of which is specific for the CSC phenotype identified in
a particular tumor type. Markers for PCa stem cells include cell surface proteins such as
CD44, CD133, CD117, ABC transporters (ABCB1, ABCG2), cytoplasmic proteins such
as NES, enhanced aldehyde dehydrogenase (ALDH) activity, and nuclear proteins such
as Sox-2, Oct 3/4, and Nanog [84]. Table 1 highlights the validated CSC markers utilized
in PCa studies.
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Table 1. Putative prostate CSC Makers Identified in PCa Cell Lines, Animal Xenografts
and Human Primary PCa Tissues.

From Ni J et al., 2014 [79]
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Therapies Targeting CSC pathways
Current targeting of CSCs focuses on the signaling pathways upregulated in stem
cells that are specific to their function. These pathways include Hedgehog, Wnt, Notch,
and NFkB pathways. The Hedgehog (Hh) pathway plays an important role in regulating
CSCs in PCa by regulating target genes involved in proliferation, survival, and metastasis
[85].This pathway also promotes chemoresistance by increasing transcription of ABCB1
and ABCG2 in PCa [85]. Hh inhibitors have shown promise in vitro with numerous
clinical trials currently testing inhibitors for PCa treatment [77].
Wnt signaling contributes to CSC development, making it a promising target. As
with the Hh pathway, many therapeutic agents targeting Wnt are under clinical study
including monoclonal antibodies against the Wnt cascade and a small molecule inhibitor
that has been shown to inhibit PCa tumor growth in vitro [77].
Notch signaling is overactivated in PCa and its silencing is predicted to inhibit
tumor growth and differentiation [86, 87]. Many phamacological agents targeting Notch
signaling are undergoing clinical study including siRNAs, and monoclonal antibodies
against Notch receptors and/or ligands. GSI, a gamma-secretase inhibitor, is being
combined with bicalutamide in patients whose PCa recurs after surgery or radiation [87].
Many challenges exist with targeting CSCs, many of which involve the lack of
understanding of the underlying pathways and the genetic alterations that maintain or
create CSC-niches in the tumors. For example, targeting the biomarkers that identify
prostate CSCs and signaling pathways that sustain this population are potential targets for
novel drug development alone or in combination [79]. However, there remains a need to
better understand where CSCs originate and how they develop and are sustained. As with
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other cancers, prostate CSCs are phenotypically and functionally diverse [79], therefore,
understanding the relationship between distinct CSC populations is important to develop
strategies to target them.

Therapies to Circumvent DTX-Resistance
The main goal of novel therapies for mCRPC are to either bypass DTX-resistance
using an alternative/redundant anti-tumoral pathway or to directly inhibit the pathways
directly causing resistance. Anti-tumoral approaches worth mentioning include
Sipuleucel-T, abiraterone acetate, enzalutamide, and alpharadin. Sipuleucel-T is an
immunotherapy approved in 2010 by the FDA. This anti-tumor vaccine resulted in a 4.1
month improvement in median overall survival compared to placebo group [88]. Lastly,
the radiopharmaceutical alpharadin radium-223 chloride was found to be effective in
patients with CRPC and mCRPC with no differences found with previous DTX usage
[89]. Despite the increased survival reported for each new treatment, effectiveness is
limited.
The number of therapies available to overcome development of DTX-resistance
are far less numerous [32]. Only two are FDA approved for use in CRPC, including CTX
and denosumab. As previously mentioned, CTX is a DTX-related taxane that was
developed to limit drug efflux and thereby make it more effective [11]. Denosumab is an
antibody targeted against the receptor activator of nuclear factor !B ligand (RANK-L).
This treatment was developed to inhibit the NF!B survival pathway, which is activated
by taxane therapy [32].
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Many promising treatments developed to circumvent DTX-resistance pathways
have failed to show success in the clinical setting. Of importance is OGX-011 or
Custirsen, a next generation oligonucleotide targeting sCLU. Despite initial sucess in
preclinical models and Phase I and II studies, Custirsen in combination with DTX or
CTX failed to show any benefit over chemotherapy alone in Phase III studies [90, 91],
with the SYNERGY trial reporting 5% adverse effects in the DTX, prednisone, and
Custirsen group leading to patient death [91]. Another promising treatment was the IL-6
monoclononal antibody siltuximab (CNTO 328). This Phase II study involved siltuximab
treatment in combination with mitoxantrone compared to mitoxantrone alone.
Unfortunately, the study did not meet its primary endpoint and resulted in no apparent
improvement in survival outcomes [92].

RNA Sequencing as an Approach to Transcriptome Profiling
Next generation sequencing (NGS) has revolutionized transcriptomics by making
it feasible to analyze expressed genes from any tissue or species without needing to
identify known transcripts. This is significant because previous global RNA analysis was
restricted only to known splice variants or nucleotide sequences. RNA sequencing (RNAseq) is a more sensitive technique compared to microarrays, with a longer range and the
ability to determine allele-specific expression making it the current preferred method of
large-scale RNA studies. Unfortunately, the data produced from these studies is dense
and complex, requiring significant time commitments to mine the data sets and
extrapolate the results [93].
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Hypothesis and Purpose of Dissertation Work
Understanding the molecular mechanisms underlying the acquisition of PCa
chemoresistance is critical for developing novel combinatorial therapies for the
prevention or reversal of taxane-resistance, which will improve patient survival and
ultimately result in a curative option for mCRPC. Several mechanisms involved in the
acquisition of DTX-resistance have been identified, including the role of multidrug
resistance pumps (e.g. ABCB1), impaired apoptotic pathways (e.g. Bcl-2), cytokine and
chemokine induction (e.g. IL-6, CCL2), alterations in microtubule structure and function,
NF-kB pathway activation, and upregulation of stress proteins (e.g. Hsp27, clusterin, and
LEDGF/p75) [11, 26, 31, 32].
Unfortunately, efforts aimed at targeting or disrupting some of these pathways in
the clinical setting have been largely unsuccessful [13]. This is illustrated by the recent
failure of phase III clinical trials with Custirsen [90, 91]. Such failures highlight the
importance of continued efforts towards discovering new mechanisms and molecular
pathways associated with the taxane-resistant phenotype. Given the scarcity of genomic
studies examining the transcriptomic programs activated during development of DTXresistance in mCRPC, we performed RNA-seq on DTX-sensitive and DTX-resistant
mCRPC cells in an effort to identify new gene pathways potentially involved in taxane
resistance. Due to the inconsistency in the literature regarding AR-DTX interactions [63,
64], we chose not to focus on the role of AR in DTX and avoided the use of AR-positive
cell lines. As such, PC3 and DU145 are AR-negative CRPC cell lines which are often
used for DTX-resistance studies, and were deliberately chosen as cellular models for the
purposes of this study.

26

We hypothesized that the RNA sequencing will reveal differentially expressed
upregulated and downregulated genes when cells transition from DTX-sensitivity to
DTX-resistance. The goal of the present study is to identify new therapeutic targets that
are critical for the acquisition of DTX-resistance. This will lead to the development of
new therapies to halt the progression of advanced PCa, resulting in a cure for this
malignancy.
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Abstract
Patients with metastatic castration-resistant prostate cancer (mCRPC) develop
resistance to conventional therapies including docetaxel (DTX). Identifying molecular
pathways underlying DTX resistance is critical for developing novel combinatorial
therapies to prevent or reverse this resistance. To identify transcriptomic signatures
associated with acquisition of chemoresistance we profiled gene expression in DTXsensitive and -resistant mCRPC cells using RNA sequencing (RNA-seq). PC3 and
DU145 cells were selected for DTX resistance and this phenotype was validated by
immunoblotting using DTX resistance markers (e.g. clusterin, ABCB1/P-gp, and
LEDGF/p75). Overlapping genes differentially regulated in the DTX-sensitive and resistant cells were ranked by Gene Set Enrichment Analysis (GSEA) and validated to
correlate transcript with protein expression. GSEA revealed that genes associated with
cancer stem cells (CSC) (e.g., NES, TSPAN8, DPPP, DNAJC12, and MYC) were highly
ranked and comprised 70% of the top 25 genes differentially upregulated in the DTXresistant cells. Established markers of epithelial-to-mesenchymal transition (EMT) and
CSCs were used to evaluate the stemness of adherent DTX-resistant cells (2D cultures)
and tumorspheres (3D cultures). Increased formation and frequency of cells expressing
CSC markers were detected in DTX-resistant cells. DU145-DR cells showed a 2-fold
increase in tumorsphere formation and increased DTX resistance compared to DU145DR 2D cultures. These results demonstrate the induction of a transcriptomic program
associated with stemness in mCRPC cells selected for DTX resistance, and strengthen the
emerging body of evidence implicating CSCs in this process. In addition, they provide
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additional candidate genes and molecular pathways for potential therapeutic targeting to
overcome DTX resistance.

Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second
cause of cancer deaths among American men [1]. For men diagnosed with advanced PCa,
treatment with curative intent is no longer an option, and androgen deprivation therapy
(ADT) remains the main therapeutic modality [2, 3]. Despite its initial effectiveness at
reducing tumor growth, ADT ultimately fails, resulting in metastatic castration-resistant
prostate cancer (mCRPC), a lethal stage of the disease that is marked by recurrence of
elevated prostate specific antigen (PSA) and progression of metastatic lesions [3, 4].
Since 2004, the standard first-line chemotherapeutic agent for the treatment of mCRPC
has been the taxane drug docetaxel (DTX), a microtubule-stabilizing agent that
moderately increases overall survival [4, 5]. Eventually, however, chemoresistance
occurs in all DTX-treated patients resulting in continued disease progression [6]. In
recent years, new treatment options for mCRPC have been developed, including the nextgeneration androgen receptor-targeting agents abiraterone acetate and enzalutamide,
therapeutic vaccines, and the second generation taxane cabazitaxel [6, 7]. Unfortunately,
these novel therapeutic agents, which are often administered sequentially or in
combination with DTX, only moderately improve overall patient survival due to the
development of therapy resistance.
Understanding the molecular mechanisms underlying the acquisition of PCa
chemoresistance is critical for developing novel and effective combinatorial therapies for
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the prevention or reversal of taxane resistance. Several mechanisms involved in the
development of DTX-resistance have been identified, including the increased expression
and activity of multidrug resistance pumps (e.g. ABCB1/P-gp/MDR1), impaired
apoptotic pathways (e.g. Bcl-2), cytokine and chemokine induction (e.g. IL-6, CCL2),
alterations in microtubule structure and function, NF-kB pathway activation, and
upregulation of stress survival proteins (e.g. Hsp27, clusterin, and LEDGF/p75) [2, 8, 9].
Unfortunately, efforts aimed at targeting or disrupting some of these pathways in the
clinical setting have been largely unsuccessful [4]. This is illustrated by the recent failure
of phase III clinical trials with Custirsen, a second generation oligonucleotide
administered in combination with DTX designed to disrupt the production of clusterin
(CLU), a cytoprotective anti-apoptotic chaperone protein overexpressed in PCa [10, 11].
Such failures highlight the importance of continued efforts towards discovering new
mechanisms and molecular pathways associated with the taxane-resistant phenotype.
Chemoresistance, the primary cause of treatment failure, is driven by the survival
of subpopulations of prostate tumor cells that eventually contribute to aggressive disease
progression, characterized by metastasis to the bone and vital organs [12]. In addition,
PCa tumors are highly heterogeneous, with many areas containing genetically distinct
clones [13], a characteristic that also contributes to therapy resistance and tumor relapse
[12]. An emerging explanation for both the development of resistance and the cellular
heterogeneity in PCa and other solid tumors is the cancer stem cell (CSC) hypothesis,
which proposes that solid tumors are organized hierachically with only a minor subset of
cells capable of tumor-initiating and tumor-propagating capacity [12, 14].
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Recent studies revealed that markers associated with epithelial-to-mesenchymal
(EMT) transition and CSCs are elevated in DTX-resistant mCRPC cells [15, 16], and that
CSCs derived from immortalized normal prostate epithelial cells showed increased DTX
resistance compared to parental adherent cells [17]. Given the scarcity of next generation
sequencing (NGS) studies examining the transcriptomic programs activated during
development of DTX-resistance in mCRPC, we performed an RNA sequencing (RNAseq) analysis on DTX-sensitive and DTX-resistant mCRPC cells in an effort to identify
gene pathways potentially involved in taxane resistance. GSEA analysis of the
overlapping upregulated genes in DTX-resistant PC3-DR and DU145-DR cells revealed
an induction of a transcriptomic program associated with stemness as cells transitioned
from DTX sensitivity to resistance. To validate this finding, we characterized the CSC
phenotype in tumorspheres from DTX-resistant PC3-DR and DU145-DR cells using CSC
markers previously validated in prostate tumorspheres. Understanding the role of CSCs in
PCa chemoresistance, including the transcriptomic pathways that define their activation
and maintenance is critical to identifying new targets for combinatorial therapies aimed at
circumventing taxane resistance in mCRPC.

Results
PC3-DR and DU145-DR Cells Upregulate Markers of Taxane Resistance
We developed PC3-DR and DU145-DR cell lines by selecting and expanding the
surviving cells in the presence of incrementally increasing concentrations of DTX until
cells could be maintained in 10 nM DTX with minimal cell death [8, 18]. Our group
reported recently that these DTX-resistant cell lines are also resistant to paclitaxel and

40

cabazitaxel, other clinically relevant taxanes [8]. We also demonstrated that these DTXresistant cells overexpress the stress oncoprotein Lens Epithelium Derived Growth Factor
of 75 kD (LEDGF/p75), and that depletion of this protein partially resensitized these cells
to DTX [8, 18]. In the present study, we confirmed that the DTX-resistant PC3-DR and
DU145-DR cell lines used in the RNA-seq analysis and other experiments displayed
significant upregulation of proteins previously implicated by our group and others in PCa
progression and DTX resistance [8, 9, 19-23] including LEDGF/p75, CLU, and ATPbinding cassette sub-family B member 1 (ABCB1), compared to the sensitive cells
(Figure 2A-2C). This validation step was critical prior to initiating our RNA-seq analysis
comparing the transcriptome profiles of DTX-sensitive and DTX-resistant PCa cell lines.
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Figure 2. DTX-resistant PC3 and DU145 Cell Lines Upregulate Known Markers of
DTX Resistance. Upper panel: Western blots of (A) LEDGF/p75, (B) CLU, and (C)
ABCB1 showing upregulation of these proteins in DTX-resistant PC3 and DU145
mCRPC cells, compared to the parental, sensitive cells. Bottom panel: quantification
of fold change in protein expression (A n=8, B n=5, C n=4 independent experiments).
*P<0.05; **P < 0.05; ***P < 0.001. Due to the absence of ABCB1 expression in the
parental PC3 and DU145 cells, for quantification purposes we normalized its
expression in these cells to an arbitrary value of 0.10. Error bars represent mean
standard deviation (SD).

42

RNA-seq Analysis Revealed Upregulation of Genes Associated with CSC-like
Characteristics
Principal Component Analysis (PCA) 3D mapping of our RNA-seq data
demonstrated that the DTX-sensitive PC3 and DU145 cells were clearly separated from
each other based on global transcriptome expression profiles (Figure 3A). However, once
these cell lines became DTX-resistant they were clustered together spatially, suggesting
an acquired similarity in transcriptomic profiles. Global gene heat map also demonstrated
the clustering of the DTX-resistant cell lines based on their transcriptome expression
profiles (Figure 4). Our RNA-seq data revealed that of 31,864 total genes detected, 3,754
and 2,552 were differentially upregulated with statistical significance (FDR > 0.05, and
fold change [FC] > 2) in the DU145-DR and PC3-DR cells, respectively, compared to
their DTX-sensitive counterparts (Figure 3B, 3C). Of these genes, 1,254 overlapped
between the PC3-DR and DU145-DR cells. GSEA of the top 25 ranked overlap genes
between the DTX-sensitive and DTX-resistant PC3 and DU145 cells revealed a distinct
on/off switch of genes, suggesting a pattern of upregulated/downregulated genes
associated with the development of DTX-resistance in both cell lines (Figure 3D) (see
Figure 5 for top 50 ranked genes). An exhaustive PubMed literature search also revealed
that 17 of the top 25 (70%) ranked overlapping genes upregulated in the DTX-resistant
cell lines have been shown to be associated with or contribute to a CSC phenotype (Table
2). Top downregulated genes are listed in Table 3.
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homolog
homolog (avian)
(avian)
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Figure 3. Gene Expression Profiling Analysis Reveals Upregulation of CSC-associated
Genes. (A) Principal component Analysis (PCA) mapping demonstrates clustering of
DTX-resistant cell lines based on gene expression profiles. (B) Diagram showing the
distribution of statistically significant differentially regulated genes in each cell line,
comparing DTX-resistant (DR) to sensitive (S). (C) Diagram demonstrating the overlap
or shared genes common to both PC3 and DU145 cells, comparing DR to S. (D) Heatmap
of the top ranked genes generated using GSEA analysis on the common overlap genes
between both sensitive PC3 and DU145 cells compared to PC3-DR and DU145-DR. Red
represents fold upregulation and blue represents fold downregulation. (E) GSEA gene set
pathway analysis revealed one pathway to be significantly enriched in the DTX-resistant
PC3-DR and DU145-DR cells compared to sensitive PC3 and DU145 cells (P= 0.032)
involving precursor metabolites and energy. A positive value indicates correlation with
the sensitive phenotype and negative value indicates correlation with the resistant
phenotype.
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Figure 4: Hierarchical Clustering Heat Map of Global Gene Analysis
for all Cell Lines (PC3, DU145, PC3-DR, and DU145-DR).
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Fig
Fig 1:
1: heat_map
heat_map
Fig 1: heat_map

Figure 5. GSEA Generated Heat Map of the Top-ranked 50 Overlap Genes.
Significantly downregulated (blue) or upregulated (red) between DTX-sensitive PC3
and DU145 compared to DTX-resistant PC3-DR and DU145-DR cells.
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Table 2. GSEA Top-ranked RNA-seq Upregulated Genes
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'

'

04.135'

3.890'

4.956'

YES

03.967'

3.196'

3.083'

YES

'

'

'

'

03.909'

2.925'

1.439'

YES

'

'

'

'

03.908'

2.652'

3.861'

YES

03.885'
03.806'
03.725'
03.685'
03.641'
03.633'
03.622'

3.083'
3.477'
2.409'
2.779'
2.798'
2.690'
2.355'

3.990'
5.980'
3.432'
2.695'
2.597'
2.673'
2.989'

YES
YES
YES
YES
YES
0'
0'

'

'

'

'

03.591'

2.538'

4.071'

YES'

03.586'

2.460'

3.167'

0'

03.579'
03.548'

2.538'
2.535'

3.345'
3.679'

0'
0'

03.501'
03.455'
03.452'
03.437'

2.470'
2.784'
2.271'
2.552'

3.158'
2.488'
2.657'
2.371'

0'
YES
YES
0'
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Table 3. GSEA Top 25-ranked RNA-seq Downregulated Genes
!

!
Gene!Title!

Gene!
Name!

Rank!
Score!
(GSEA)!

Log2!Fold!
Change!PC3!
vs.!PC3BDR!

Log2!Fold!
Change!
DU145!vs.!
DU145BDR!

KRT7'

keratin'7'

4.702'

07.497'

07.843'

HLA0C'

major'histocompatibility'complex,'class'I,'C'

4.500'

05.337'

04.225'

LAMA3'

laminin,'alpha'3'

4.494'

04.056'

04.376'

PLA2G16'

phospholipase'A2'Group'XVI'

4.332'

03.905'

04.489'

'
ERBB2'

v0erb0b2'erythroblastic'leukemia'viral'oncogene'
homolog'2,'neuro/glioblastoma'derived'
oncogene'homolog'(avian)'

'
4.267'

'
03.339'

'
03.632'

AIFM2'

apoptosis'inducing'factor,'mitochondria'
associated'2'

4.193'

04.127'

03.373'

C1ORF116'

chromosome'1'open'reading'frame'116'

4.157'

03.317'

03.529'

'

'

'

'

PSMB8'

proteasome'subunit'beta'type,'8'(large'
multifunctional'peptidase'7)'

4.133'

06.159'

03.699'

JUP'

junction'plakoglobin''

4.100'

04.461'

03.666'

FURIN'

furin'(paired'basic'amino'acid'cleaving'
enzyme)'

4.059'

03.102'

03.391'

ALS2CL'

ALS2'C0terminal'like'

4.032'

03.975'

03.194'

LAM83'

laminin,'beta'3'

3.984'

03.587'

04.206'

'

protein'kinase'(cAMP0dependent,'catalytic'
inhibitor'gamma'

'

'

'

3.963'

03.214'

02.976'

sema'domain,'immunoglobin'domain'(Ig),'short'
basic'domain,'secreted,'(semaphorin)'3C'

'

'

'

SEMA3C'

3.939'

02.957'

03.166'

MROH6'

maestro'heat0like'repeat'family'member'6'

3.906'

04.171'

02.881'

TNS3'

tensin'3'

3.858'

02.992'

02.889'

LY6E'

lymphocyte'antigen'6'complex,'locus'E'

3.834'

03.344'

02.945'

SSH3'

slingshot'homolog'3'(Drosophila)'

3.801'

02.733'

02.984'

PTPRF'

protein'tyrosine'phosphatase,'receptor'type,'F'

3.765'

02.463'

03.473'

'

'

'

PKIG'
'

'

WNT7B'

wingless0type'MMTV'integration'site'family,'
member'7B'

3.686'

02.694'

04.630'

PTK28'

PTK2B'protein'tyrosine'kinase'2'beta'

3.632'

03.658'

03.552'

CAPN5'

calpain'5'

3.614'

02.852'

02.380'

solute'carrier'family'27'(fatty'acid'transporter),'
member'3'

'

'

'

3.592'

03.285'

02.310'

microtubule'associated'monoxygenase,'
calponin'and'LIM'domain'containing'2'

'

'

'

MICAL2'

3.590'

02.301'

02.910'

GCA'

grancalcin,'EF0hand'calcium'binding'protein'

3.575'

03.679'

02.472'

'

SLC27A3'
'
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Gene Set Enrichment Analysis (GSEA) also identified the gene set
“GO_Generation of Precursor Metabolites and Energy” as the only significantly enriched
pathway in the DTX-resistant PC3-DR and DU145-DR cells (P = 0.032) (Figure 3E).
This analysis yielded 8 genes (NADUFAF2, ENPP1, NDUFAB1, NDUFA8, PFKM,
GNPDA1, CYC1, MYC) that were positive for core enrichment in this gene set. Of these
genes, ectonucleotide phosphodiesterase 1 (ENPP1), cytochrome c-1 (CYC1), NADH
dehydrogenase 1 alpha/beta subcomplex 1 (NADUFAB1), and v-myc myelocytomatosis
viral oncogene homolog (MYC) have been associated with stem cell maintenance,
phenotype acquisition, or reprogramming [24-29], suggesting that upregulation of
specific genes involved in metabolism may contribute to an enrichment of cells with
CSC-like characteristics (Figure 3E). Taken together, the RNA-seq analysis of transcript
expression in DTX-sensitive vs. DTX-resistant PCa cell lines provides evidence for the
acquisition of a transcriptomic program associated with stemness as a mechanism
contributing to the development of DTX-resistance.

Validation of Transcript and Protein Expression of Selected Genes in DTX-resistant
Cells Confirmed RNA-seq Results
To confirm the RNA-seq data, we performed in-house qPCR validation on
selected genes that showed robust upregulation in both PC3-DR and DU145-DR cells,
compared to the sensitive, parental cell lines. The selection of specific genes for
validation was determined by two criteria: the GSEA ranked gene order (Table 2 and
Table 3), and exhaustive literature searches implicating these genes in cancer, PCa,
therapy resistance, DTX resistance, stem cells, CSCs, or EMT. For our in-house
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validation of RNA-seq data, new RNA samples were extracted from a different set of
DTX-sensitive and DTX-resistant cells than those used for the RNA-seq analysis.
Consistent with the RNA-seq results, transcript expression of dipeptidyl peptidase 4
(DPP4), tetraspanin 8 (TSPAN8), nestin (NES), DNAJ heath shock protein family
member C12 (DNAJC12), fatty acid binding protein 5 (FABP5), and block of
proliferation 1 (BOP1) were upregulated in PC3-DR and DU145-DR cells compared to
the corresponding sensitive cell lines (Figure 6). As an internal control for in-house
validation, we also chose two genes found robustly downregulated in the RNA-seq
results, transglutaminase 2 (TGM2) and ATP-binding cassette subfamily C member 3
(ABCC3). Transcript expression of both genes was robustly downregulated in PC3-DR
and DU145-DR cells compared to the sensitive cell lines, further confirming the RNAseq results (Figure 6). The magnitude of fold-increase observed for each of these genes
was more robust in DU145-DR cells than in PC3-DR cells, suggesting cell-type
dependent differences in gene expression during the acquisition of resistance to DTX.
Despite these differences, P values were consistently < 0.01 for each of the selected
genes in both DTX-resistant cell lines.
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Figure 6. In-house qPCR Validation of the Expression of Selected Top-ranked Genes
from RNA-seq Results in DTX-Sensitive and DTX–Resistant mCRPC cells. qPCR
validation for selected genes in (A) PC3 vs. PC3-DR and (B) DU145 vs. DU145-DR
cells. White bars represent parental PC3 or DU145 and colored bars represent PC3-DR
or DU145-DR. *P <0.05; **P < 0.05; ***P < 0.001. All RNA samples were analyzed
in at least three independent experiments using at least three biological replicates per
experiment. Error bars represent mean SD.
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After validation of the transcript expression of selected genes in the DTXresistant PC3-DR and DU145-DR cells, we sought to confirm corresponding protein
upregulation in these cells compared to their sensitive counterparts by immunoblotting
using specific antibodies. Significant upregulation of DPP4, TSPAN8, NES, DNAJC12,
FABP5, and BOP1 was observed in the PC3-DR and DU145-DR cells, consistent with
the qPCR and RNA-seq results (Figure 7A-7F). Also consistent with the RNA-seq and
qPCR results, the protein expression of TGM2 was downregulated in the DTX-resistant
cells (Figure 7G).
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Figure 7. Protein Expression Validation of RNA-seq Results in DTX-sensitive and DTXresistant mCRPC Cells. Representative Western blot images and protein fold change
quantification are shown for (A) DPP4 (n= 3), (B) TSPAN8 (n= 4), (C) NES (n= 6), (D)
DNAJC12 (n= 4), (E) FABP5 (n= 7), (F) BOP1 (n=4), and (G) TGM2 (n=4). *P< 0.05;
**P< 0.05; ***P< 0.001. All proteins were analyzed in at least three independent
experiments. Error bars represent mean ± SD.
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Analysis of Cancer Gene Microarray Datasets Reveals Consistent Upregulation of
DNAJC12, FABP5, and BOP1 in PCa Tissues
After confirming that transcript and protein expression of selected genes reflected
the upregulation observed in the RNA-seq analysis, we sought to examine the expression
of these genes in human PCa tissues. Transcript expression of the selected genes in PCa
tissues, compared to normal prostate tissue, was analyzed using 16 PCa gene expression
microarray datasets from the Oncomine database. All 16 datasets had data for FABP5,
whereas data for DPP4 and TSPAN8 were available in 15 datasets, and data for BOP1,
DNAJC12 and NES were available in 14, 10 and 8 datasets, respectively.
Of the selected genes, DNAJC12, FABP5, and BOP1 were the most consistently
upregulated in prostate tumors compared to normal prostate tissues in the dataset
collection (Figure 8A-8C), with significant upregulation of DNAJC12 in 6 of the 14
datasets (Figure 8A), FABP5 in 14 of the 16 data sets (Figure 8B), and BOP1 in 7 of the
14 datasets (Figure 8C). DPP4 and TSPAN8 transcripts were significantly upregulated
only in 4 of the 14 datasets (Figure 8D-8E). Interestingly, significant upregulation of
NES transcript was detected only in 1 of the 8 datasets (Figure 8F). The magnitude of the
fold-increase observed for the individual genes was modest, with only FABP5 showing
over 2-fold increase in multiple datasets. However, the P values were <0.01 for most of
the DNAJC12, FABP5, and BOP1 datasets, indicating that upregulation of these
transcripts is highly significant in PCa tissues compared to normal tissues. On the other
hand, NES transcripts were significantly downregulated in 4 of the 8 datasets, whereas
DPP4 and TSPAN8 transcripts displayed significant downregulation in 1 and 2 out of 15
datasets, respectively.
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DNAJC12

DPP4
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FABP5
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TSPAN8

F
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Figure 8. Expression of Selected Top-Ranked Genes in Clinical PCa Tissues. Fold
change between transcript expression levels of selected top ranked genes (from RNA-seq
analysis) in prostate tumors versus normal prostate tissues as derived from cancer gene
microarray datasets in the Oncomine database. Individual dataset names appear in the
legend box at the right. P values for the differences in gene expression between PCa and
normal prostate tissues were obtained from Oncomine. The number of samples in each
dataset is different, therefore higher fold change does not always correspond to statistical
significance. *P< 0.05, **P< 0.01, ***P< 0.001.
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PC3-DR and DU145-DR Cells Upregulate Markers Associated with EMT and CSCs
The observation that highly ranked genes (GSEA) in the RNA-seq results were
associated with CSC development or are known markers of CSCs (e.g. NES, DPP4,
TSPAN8), led us to assess the expression of established EMT and CSC markers in our
DTX-resistant cell lines. Microscopic assessment of DTX-resistant cells revealed a
mesenchymal phenotype with clearly defined edges and the classical spindle-shaped
morphology, compared to the flattened, polygonal-shaped sensitive PC3 and DU145
(Figure 9A). Using multicolor flow cytometry, we analyzed the following populations in
both DTX-sensitive and DTX-resistant cells: E-cadherin positive and N-cadherin positive
(Figure 9B, 9C), as well as CD44+ and CD44+/ CD24- (Figure 10A, 10B). Consistent
with their mesenchymal phenotype, DTX-resistant cells showed significantly reduced Ecadherin expression compared to DTX-sensitive cells, concomitant with an increase in Ncadherin expression, as determined by flow cytometry (Figure 9B, 9C) and
immunoblotting (Figure 9D, left two panels). Notably, loss or downregulation of Ecadherin is associated with poor prognosis in PCa [16]. We also observed that loss of Ecadherin in the DTX-resistant cell lines was coupled with upregulation of Vimentin
(Figure 9D, center panel) and transcription factors Snail and Twist (Figure 9D, center and
right two panels).
Vimentin, a well-established marker of EMT [30], was robustly and significantly
upregulated in the PC3-DR cells compared to sensitive PC3 but its upregulation did not
reach statistical significance in DU145-DR cells compared to sensitive DU145. Both
Snail and Twist are known to repress E-cadherin expression, with Twist having a dual
role in contributing to the upregulation of N-cadherin expression [15, 16, 30]. Taken
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together, these findings support growing evidence implicating EMT in PCa DTXresistance [15, 16, 31].
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Figure 9. DTX-resistant mCRPC Cells Exhibit a Mesenchymal-like Phenotype
Compared to DTX-sensitive Cells. (A) Differences in morphology between DTXsensitive and DTX-resistant PC3 and DU145 cells visualized by Hoffman modulation
contrast microscopy (scale bar set at 40 µm). (B) Percent of live PC3 and DU145 cells
(DTX sensitive and -resistant) that stained positive for E-cadherin and N-cadherin as
determined by flow cytometry (n=3 biological replicates) *P< 0.05, **P< 0.01, ***P<
0.001. (C). Representative flow charts of bar graph data showing downregulation of Ecadherin and upregulation of N-cadherin in the DTX-resistant cell lines. (D)
Representative Western blots showing expression (upper panels) and quantification
(lower panels) of E-cadherin (n=3), N-cadherin (n=3), Vimentin (n=3), Snail (n=3), and
Twist (n=3). *P< 0.05, **P< 0.01,***P< 0.001. Error bars represent mean ± SEM.
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In addition to these findings, we observed that the DTX-resistant cell populations
displayed a higher frequency of cells expressing established CSC markers (Figure 10).
CD44, one of these markers, is a multifunctional class I transmembrane glycoprotein that
is highly expressed in most cancer types, where it contributes to tumor progression [32].
While we observed a significant proportion of PC3-DR cells with CD44+ expression
compared to sensitive cells, there was no significant increase in the frequency of CD44+
cells in the DU145-DR population (Figure 10A, left two panels). However, because
CD44 is expressed in almost all normal and cancer cells, specifically in normal prostate
and PCa cells, there is a reported discrepancy and ambiguity regarding the functional
aspects of this marker in prostate CSC maintenance [32]. This discrepancy is supported
by our observation that sensitive DU145 cells showed high CD44+ expression (Figure
10A, 10B, left panels), and has been circumvented by using CD44 in combination with
other markers to detect CSC subsets in PCa [32-36].
To better refine our detection of the putative CSC population in DTX-resistant
cells, we used the well-validated combination of CD44+/CD24- [32, 35, 36]. CD24 is a
luminal cell surface protein that contributes to metastasis and functions in cell-cell and
cell-matrix interactions [32, 33, 36]. Because prostate CSCs arise from the basal cell
compartment, the CD44+/CD24- marker combination is commonly used to identify these
cells [32, 33]. We observed that both PC3-DR and DU145-DR cells contained substantial
CD44+/CD24- subpopulations compared to the sensitive PC3 and DU145 cells (Figure
10A, 10B, right two panels).
Elevated aldehyde dehydrogenase (ALDH) activity is also emerging as a
functional marker of a CSC-like phenotype because of its importance for CSC
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maintenance, signaling, and drug resistance [37]. To further confirm the acquisition of
CSC-like characteristics in the DTX-resistant cells, we measured by flow cytometry the
frequency of Aldefluor+ cells in our DTX-resistance cells compared to sensitive cells.
Both PC3-DR and DU145-DR showed robust increase of ALDH activity compared to
their sensitive counterparts (Figure 10C, 10D).
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C o m p %B 2 %A )::)C D 2 4 %B 2 %A

Figure 10. DTX-resistant mCRPC Cells Upregulate Markers Associated with CSC-like
Characteristics Compared to DTX-sensitive Cells. (A) Percent of CD44+ and CD44+/
CD24- cells for PC3 vs PC3-DR and DU145 vs DU145-DR, with (B) representative flow
cytometry plots showing compensation windows used in the FMO analysis for each
marker. Flow data is represented as frequency of live cells determined by annexin-V
staining. (C) PC3-DR and (D) DU145-DR cells have a significantly greater percentage of
ALDH+ cells compared with sensitive PC3 and DU145 cells as determined by aldefluor
assay (+DEAB control used for gating). Representative flow plots are shown together
with bar graphs. All flow measurements were acquired from at least 3 independent
experiments conducted separately. **P< 0.01, ***P< 0.001. Error bars represent mean ±
SEM.
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Increased Tumorsphere Formation Capacity and DTX-resistance in DU145-DR Cells
Upon confirmation of increased frequency of cells expressing EMT and CSC
markers in the adherent (2D) DTX-resistant cell cultures, we sought to examine and
compare tumorspheres (3D cultures) formed by sensitive and resistant DU145 cells.
Tumorsphere formation is a widely used functional approach for enriching CSC
populations, especially when specific surface CSC markers are not well defined or
change with tumor heterogeneity [38-40]. We chose to focus these studies on the DU145
cell line because its DTX-sensitive cells formed large numbers of tumorspheres,
consistent with previous reports that this cell line has a robust ability to form spheres
even in the absence of external growth factors or drugs [34]. We observed that under
tumorsphere-forming conditions, DU145-DR cells showed a 2.3-fold increase in
tumorspheres compared to sensitive DU145 cells, as evidenced by phase contrast (4X)
microscopic examination (Figure 11A, 11B). DU145-DR tumorspheres were loosely
clustered, tethered together in grape-like clusters to form large aggregates (Figure 11C).
This morphology was a stark difference from the tightly compact tumorspheres of
sensitive DU145 cells.
Consistent with our analysis of adherent DTX-resistant cells (2D), flow cytometry
analysis of DTX-resistant tumorspheres (3D) revealed a decreased frequency of Ecadherin expressing cells concomitant with increased frequency of N-cadherin expressing
cells in the DU145-DR 3D cultures compared to DU145 3D cultures, (Figure 11D, 11E,
left two panels). In addition, we detected increased frequencies of CD44+ and CD44+/
CD24- populations in DU145-DR 3D compared to DU145 3D cultures (Figure 11D, 11E,
right two panels). Furthermore, consistent with the 2D data, DU145-DR tumorspheres
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had a significantly higher number of Aldefluor+ cells than DU145 tumorspheres (Figure
11F).
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Figure 11. Tumorsphere Formation Capacity is Higher in DTX-resistant DU145 Cells
Compared to Sensitive Cells. (A) Phase contrast microscopy images of DU145 and
DU145-DR tumorspheres (3D) with (B) quantification of tumorsphere percentage using
Image J software. (C) Tumorsphere morphology visualized using Hoffman modulation
contrast microscopy (scale bar set at 40 µm). (D) Percent of live cells positive for the cell
surface markers E-cadherin and N-cadherin, and CSC markers CD44+/ CD24-, CD44+/
CD24-, with (E) representative flow cytometry plots. (F) Representative flow cytometry
plots showing increased percentage of ALDH+ cells in DU145-DR tumorspheres as
determined by aldefluor assay with bar graphs. All flow measurements were acquired
from at least 3 independent experiments conducted separately. *P< 0.05, **P< 0.01,
***P< 0.001. Error bars represent mean ± SEM.
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Other groups have demonstrated that tumorspheres derived from DU145 3D cells
are more resistant to DTX treatment compared to DU145 2D cells [40, 41]. To further
investigate the link between CSCs and DTX-resistance, we sought to determine if our
DU145-DR tumorspheres were more resistant to DTX compared to DU145-DR 2D cells
after exposure to increasing concentrations of DTX for 72 hours. Using propidium iodide
(PI) staining of dead cells followed by flow cytometric analysis, we found that DU145DR 3D tumorspheres were significantly more resistant to 10 nM DTX, the maintenance
dose of DTX-resistant cell lines compared to the DU145-DR 2D cells grown in
monolayer (Figure 12A, 12B). There were no statistical differences, however, at other
lower or higher doses (Figure 12A), or at 24 or 48-hour time points (data not shown).
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Figure 12. DU145-DR Derived Tumorspheres Show Increased Resistance to DTX
Compared to DU145-DR Adherent Cells. (A) DU145-DR adherent and tumorsphere
cells treated with increasing concentrations of DTX (nM range). (B) DU145-DR 3D
tumorspheres were more resistant to 10 nM DTX than the adherent DU145-DR 2D
cells. All samples were normalized to untreated controls and to DU145-DR 3D
percent viability. All measurements were acquired from at least 3 independent
experiments with 3 biological replicates each. *P< 0.05. Error bars represent mean
SEM.
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Discussion
There is a critical need for new drugs targeting non-traditional molecular targets
that could be used alone or in combination with current agents for the treatment of
therapy-resistant mCRPC. The present study used an RNA-seq approach to define
transcriptomic signatures associated with DTX-resistance with the ultimate goal of
identifying potentially novel therapeutic targets for overcoming this resistance. For these
studies, we chose androgen-refractory PC3 and DU145 cells, which are widely used as
cellular models that emulate late-stage mCRPC disease. While sensitive to DTXtreatment, these cell lines become resistant to the clinically relevant taxanes DTX,
cabazitaxel, and paclitaxel upon incremental exposure to DTX and selection of surviving
cells [8]. Resistance to both DTX and cabazitaxel is inevitable in mCRPC patients
undergoing chemotherapy [2], but the mechanisms underlying this resistance remain to
be clearly established.
PCa is fundamentally AR-driven especially in the context of disease initiation and
progression. Because the intraprostatic response of PCa cells to androgens depends on the
expression and sensitivity of AR, ADT has been a mainstay of PCa treatment and
typically precedes taxane chemotherapy, although data from the recent “STAMPEDE”
clinical trial showed improved patient survival when long-term primary ADT was
combined with abiraterone acetate or DTX [42]. Constitutively active AR splice variants
have been shown to be overexpressed in mCRPC and confer resistance to ADT by
inhibiting the nuclear translocation of the androgen-AR complex [43-46]. A recent study
suggested that AR splice variants may also affect sensitivity to taxanes and that tumors
predominantly expressing the ARv7 variant, associated with ADT resistance, would also
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be likely be resistant to DTX [47]. However, an independent group was unable to
replicate these results under similar experimental conditions [48]. Furthermore, another
group found that detection of ARv7 in circulating tumor cells of mCRPC patients was not
associated with taxane-resistance and that certain patients with ARv7-positive status at
baseline converted to ARv7-negative status during the course of taxane therapy, adding
uncertainty to the clinical significance of this variant in patients receiving taxanes [49].
These discrepancies also contributed to our decision to focus on the AR-negative cell
lines PC3 and DU145 for the present study.
Our RNA-seq analysis revealed over 1,200 genes that were differentially
regulated in both the PC3-DR and DU145-DR cell lines. We focused on this set of
overlap genes because differences in their expression are more likely to reflect
transcriptomic changes induced by long-term DTX treatment regardless of the PCa cell
type (e.g., PC3-bone metastasis vs. DU145-brain metastasis). Differentially expressed
genes within this pool of overlap genes could potentially be exploited as therapeutic
targets in heterogeneous metastatic prostate tumors that have acquired taxane resistance.
GSEA of our RNA-seq data revealed several top ranked genes from the overlap dataset
that an exhaustive PubMed literature review determined as being associated with tumor
aggressiveness, chemoresistance, or CSC phenotype. Of note, GSEA yielded only one
significant pathway enriched in the DTX-resistant cell lines compared to sensitive cells
that yielded 8 genes positive for core enrichment. Of these, 4 genes (ENPP1, CYC1,
NADHUFAB1, and MYC) are associated with stem cell maintenance, acquisition or
reprogramming [24-29], suggesting that in PC3 and DU145, DTX-resistance may be
driven and maintained by the acquisition of CSC-like characteristics. Determining
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metabolic differences between DTX-sensitive and -resistant mCRPC cells will be
imperative in future follow-up studies.
Using qPCR and immunoblotting, we validated several of the top upregulated
genes in the DTX-resistant cells. These included genes associated with PCa
aggressiveness, such as FABP5 and BOP1, as well as genes implicated in CSC function
such as DPP4, TSPAN8, DNAJC12, and NES. FABP5 is an intracellular lipid-binding
protein that is emerging as a critical regulator of PCa cell proliferation and putative
marker of aggressive PCa [50-53]. The robust FABP5 transcript and protein upregulation
observed in the DTX-resistant cells suggest that this protein could be a promising target
for the treatment of chemoresistant mCRPC. Another gene highly ranked in the GSEA
was BOP1, an integral component of the ribosomal RNA processing machinery that
contributes to colorectal tumorigenesis through promotion of cell migration and invasion
[54, 55]. Interestingly, the BOP1 gene is located in chromosome 8q24, a genomic region
associated with PCa aggressiveness [54] that also encompasses MYC [56], one of the top
upregulated genes in the DTX-resistant mCRPC cells revealed by our RNA-seq analysis.
An emerging stem cell marker, DPP4 (CD26) was also robustly upregulated in the
DTX-resistant cells. DPP4 is a transmembrane glycoprotein that functions as an
exopeptidase to promote cell migration through MMP-9, and contributes to the
upregulation of CD44 [57]. This protein is upregulated in many cancers and associated
with colon CSCs derived from DTX-resistant cells, which form larger and more
tumorspheres [58-61]. The robust upregulation in protein expression observed in PC3-DR
and DU145-DR suggest that DPP4 might be a prostate CSC marker that identifies a
chemoresistant phenotype. The robust transcript and protein upregulation of TSPAN8
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(TM4SF3) in the DTX-resistant cells also suggest a role for this protein in PCa
chemoresistance. TSPAN8, promotes cell-to-cell communication by regulating integrins
and other cell surface proteins [62], and its expression has been correlated with metastasis
and worse prognosis in colon cancer where it contributes to cell motility through a
complex with E-cadherin [63]. TSPAN8 is also considered a pancreatic CSC marker [64].
Genome splicing-sensitive microarray analysis revealed upregulation of TSPAN8 and
DPP4 in DU145 tumorspheres compared to adherent DU145 2D cells [65].
DNAJC12, also known as Hsp40, has been implicated in cancer but its role in
tumorigenesis is not clearly defined [66, 67]. The DNAJ family of proteins are
considered regulators of CSC function [68], and DNAJC12 transcript expression was
found to be upregulated in breast CSCs compared to adherent breast cancer cells [69].
NES, a cytoskeletal intermediate filament protein, has been associated with increased
migration in PCa cells [70], and increased NES expression correlated with high tumor
grade, invasive phenotype, and predictor of poor response to therapy [71]. Consistent
with our observation that NES is robustly upregulated in DTX-resistant mCRPC cells
with CSC-like characteristics, NES expression was previously reported in PCa
tumorspheres that showed increased chemoresistance to paclitaxel [72], and was
associated with a mesenchymal phenotype [73].
Oncomine data analysis comparing transcript expression of DPP4, TSPAN8, and
NES between prostate tumor tissues and normal tissues revealed inconsistent
upregulation of these genes in the different datasets. An explanation for this could be that
the prostate tumors used to generate most of these gene expression datasets were not
derived from advanced or chemoresistant disease. Alternatively, gene expression changes
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found in DTX-resistant cells occur in only a small subset of cells, most likely those with
stemness properties. Since tumors contain varying proportions of cells with and without
stemness properties, it will be difficult to consistently detect global gene expression
changes in CSCs present in PCa tissues since they comprise a minority of the population.
A limitation of the Oncomine database is the assessment of gene expression in normal vs.
PCa tissues without extensive clinical data (type of treatment, tumor stage, etc.) for
several of the datasets. Therefore, to further validate the expression of selected genes of
interest in clinically relevant tissues, it will be important in future studies to obtain
mCRPC biospecimens with annotated clinical data from patients with and without taxane
treatment, and that responded to or failed the treatment. We recognize, however, the
intrinsic difficulties in obtaining such biospecimens.
The beneficial effects of chemotherapeutic drugs like DTX are hindered by the
development of chemoresistance. Emerging evidence demonstrates that a small
population of CSCs present within the tumors possesses multiple redundant mechanisms
that facilitate tumor cell survival in the presence of therapeutic agents [12, 14, 17]. In
addition, the relatively non-proliferative state of CSCs makes this small population of
cells intrinsically resistant to conventional chemotherapies, most of which target rapidly
dividing cells. This resistant population comprises a tumor cell reserve that persists even
after anti-proliferative treatments and repopulates the tumor in metastatic sites [12]. The
emerging role of CSCs in the acquisition of PCa chemoresistance [12, 15, 17, 74], and
the observation that highly-ranked genes in our RNA-seq analysis were associated with a
CSC-like phenotype or genetic program, led us to characterize this population in DTXsensitive and -resistant mCRPC PC3 and DU145 cells. Putative CSCs are typically
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identified based on the presence and/or absence of several cell surface markers, the
combination of which is specific for the CSC-like phenotype identified in a particular
tumor type [71]. Our observation that the PC3-DR and DU145-DR cell cultures were
enriched with cell populations expressing several of these CSC markers, including
significantly elevated ALDH activity compared to DTX-sensitive parental cells, is
consistent with the acquisition of CSC-like characteristics. Furthermore, our finding that
DU145-DR cells have an enhanced capacity to form tumorspheres (3D) and increased
ALDH activity compared to DU145 tumorspheres, is an indicator of the increased CSClike characteristics of the resistance cells. In addition, our DU145-DR tumorspheres
showed increased resistance to 10 nM DTX, a clinically relevant dose, compared to
adherent DU145-DR cells (2D), suggesting that a CSC-like phenotype contributes to
enhanced DTX resistance. An accurate assessment of the increased tumorigenic potential
of DTX-resistant cells with CSC-like characteristics would be more effectively achieved
through in vivo studies with animal models using enriched CSC populations acquired by
cell sorting.
Targeting CSCs is a promising approach to circumvent tumor chemoresistance
[14, 17]. Current strategies focus on targeting signaling pathways upregulated in stem
cells that are specific to their function, including the Hedgehog, Wnt, Notch, and NFkB
pathways [12]. The present RNA-seq study provides additional candidate genes and
molecular pathways for potential therapeutic targeting, and contributes to the emerging
body of evidence linking CSCs to PCa chemoresistance. Future pre-clinical studies will
focus on establishing mechanistic roles of specific genes identified in our RNA-seq
analysis in the maintenance of prostate CSCs and driving taxane resistance, validating
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their expression in clinical biospecimens derived from PCa patients that failed taxane
therapy, and investigating their potential as therapeutic targets. It will also be important
to further define PCa cell-type dependent differences in the expression of CSC and
chemoresistance-associated genes, as our RNA-seq analysis demonstrated that PC3-DR
and DU145-DR cells have differentially regulated genes that are unique to each of these
cell lines. This would be critical for tackling the high heterogeneity that characterizes
prostate tumors.

Materials and Methods
Cell Lines, Antibodies, and Cell Culture
The metastatic PCa cell lines PC3 and DU145 were purchased from the American
Type Culture Collection (ATCC, Cat# ATCC-CRL-1435 and ATCC-HTB-81,
respectively). Cells were cultured as recommended by the supplier in RPMI medium
(Thermo Fisher Scientific) supplemented with 10% fetal bovine serum,
penicillin/streptomycin, and gentamicin. Cells were maintained in a humidified incubator
with 5% CO2 at 37°C. DTX-resistant (DR) PC3 and DU145 were developed as described
previously [18]. Briefly, PC3 and DU145 cells were cultured in media containing 1 nM
DTX (LC Laboratories Cat# D-1000) and surviving cells were passaged four times before
increasing the concentration of DTX. This was repeated until resistant cells could be
maintained with minimal cell death in the presence of 11 nM DTX.
Short tandem repeat (STR) profiling is a recommended and validated method for
authentication of human cell lines and tissues [75]. The importance of cell line
authentication is highlighted by the NIH initiative for rigor and reproducibility in
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scientific research [76], and is particularly important for scientific studies such as the
present one that use established cancer cell lines for pre-clinical mechanistic studies. We
utilized the STR service provided by ATCC (Cat# ATCC 135-XV) to authenticate the
PC3 and DU145 cell lines used in this study. Both cell lines matched their respective
database profiles. The DTX-resistant PC3-DR and DU145-DR cell lines were derived
from these validated PC3 and DU145 parental cell lines.

RNA Isolation and RNA-seq Library Preparation and Sequencing
Total RNA was extracted from DTX-sensitive and -resistant PC3 and DU145 cells using
the miRNeasy Mini Kit (Qiagen Cat# 217004). RNA-seq library construction and
sequencing was performed at the Loma Linda University School of Medicine Center for
Genomics. RNA-seq library was constructed using the TruSeq Stranded mRNA Low
Sample Preparation protocol (Illumina; Cat# RS-1229004DOC). Two µg of total RNA
were used as input. Each RNA sample was spiked with 1:100 ERCC RNA spike-in
control mix 1 (Life Technologies, Cat# 4456740) prior to the first step of the protocol.
All the recommended controls were used during subsequent steps including an End
Repair Control, A-Tailing Control, and Ligation Control. The RNA-seq libraries were
quantified using Qubit 3.0, and the quality of RNA-seq libraries was checked on Agilent
TapeStation. All RNA-seq libraries were sequenced on Illumina HiSeq 4000 at the Loma
Linda University Center for Genomics, with 150 bpx2, Paired-End. Quality control was
confirmed (Figure 13 and 14).
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Figure 13. Quality Assessment Metrics for RNA-seq Data. Box plots representing
interquartile range and median of (A) GC content (%) and (B) the Phred quality score
distribution over all reads across all 12 samples in each base.
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Figure 14. Quality Assessment on External RNA Spike-in Controls. (A) Percentage of
reads mapped to genomic regions including exon, intron, and intergenic region. (B) Plot
of log2(FPKM) of ERCCs detected from samples spiked with ERCC Mix1 vs log2 (spikein concentrations).
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RNA-seq Data Analysis
For mRNA-seq data visualization and analysis, we utilized pipelines that
integrated the QC (FastQC, ShortRead), trimming process (trimmomatic), alignment
(Tophat2), reads quantification (cufflinks), and differentially expressed gene (DEG)
analysis (cuffdiff) as described previously [77]. Briefly, the RNA-seq raw fastq data were
first trimmed using Trimmomatic (V0.35). The trimmed reads were aligned to the human
reference genome (NCBI GRCh38) with TopHat V2.1.1 with default parameter settings.
The aligned bam files were then processed using Cufflinks V2.2.1 for gene
quantification. Reads were then mapped to ERCC transcripts and quantified using
TopHat V2.1.1 and Cufflinks V2.1.1 with default parameter settings. Genes with FPKM
≥ 1 in all samples were used for DEG analysis. Differentially expressed genes (DEGs)
were identified by Cuffdiff with FDR > 0.05, and fold change (FC) > 2.
Hierarchical clustering heat map and PCA of global genes for all cell lines were
performed with “R” program (http://cran.r-project.org/) [78] and Partek Genomics Suite
6.6, respectively. GSEA (v3.0, Broad Institute) [79, 80], was performed to compare
parental DTX-sensitive PC3 and DU145 with DTX-resistant DU145-DR and PC3-DR.
Gene sets were obtained from published gene signatures in the Molecular Signatures
Database v1.0 (MSigDB). Analysis was run with 1,000 permutations and a classic
statistic. Normalized enrichment score and p-values were measured to find enrichments
with statistical significance (p<0.05).
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Quantitative Reverse Transcription PCR (RT-qPCR)
For confirmation of RNA-seq results, we selected specific genes for independent
in-house validation of their differential regulation in DTX-sensitive vs. -resistant cell
lines. Briefly, total RNA was extracted from cell lines using the RNAprotect reagent
(Qiagen Cat# 76526) and the RNeasy plus mini kit (Qiagen Cat# 74134). RNA (0.5 µg)
was reverse transcribed into cDNA using iScript cDNA synthesis kit (Bio-Rad Cat#
1708891). Primer sequences for gene validation were commercially synthesized by
Integrative DNA Technologies (IDT) (see Table 4). Quantitative polymerase chain
reaction (qPCR) was performed on the MyiQ real-time PCR and CFX96 Touch RealTime PCR (Bio-Rad) detection system using iQSYBR Green Supermix (Bio-Rad Cat#
170-8882) according to the manufacturer’s instructions. The cycling conditions were
95°C for 15 min, 95°C for 15s, 60°C for 60s for 35 cycles, followed by melt analysis
from 60 to 95°C. Expression levels were normalized to the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Samples were analyzed in at least
four independent biological replicates performed experimentally in triplicates.
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Table 4. Primer Sequences for qPCR
Gene!
'
DPP4'
'
TSPAN
8'
'
NES'
'
DNAJC
12'
'
FABP5'

Forward!Sequence!(5’!to!3’)!

Reverse!Sequence!(5’!to!3’)!

'
CTCCAGAAGACAACCTTGACCATT
ACAGAA'
'
TTGCTTCTGATCCTGCTCCT'

'
TCATCATCATCTTGACAGTGCAGT
TTTGAG'
'
TTTTTCACTTTCCCCTGTGG'

'
CTCCAAGAATGGAGGCTGTAGGAA'
'
CAGACAAGCATCCTGAAAACCC'

'
CCTATGAGATGGAGCAGGCAAGA'
'
TCGCCAGTGGTCATAGCGGGC'

'
ACCCTGGGAGAGAAGTTTGAAGA'

'
TGTAAAGTTGCAGACAGTCTGAGT
TTT'
'
'
'
BOP1'
CCATGCCGAGTCTTACAACCCACC' AGCAGCAACACGGCATCATCCAT
GGC'
'
'
'
ABCC3' CTGTGCACACAGAAAACCCG'
GGACACCCAGGACCATCTTG'
'
'
'
TGM2'
TAAGAGATGCTGTGGAGGAG'
CGAGCCCTGGTAGATAAA'
'
'
'
GAPDH' CGAGATCCCTCCAAAATCAA'
TTCACACCCATGACGAACAT'

!
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Immunoblotting Procedures
Whole cell lysates were prepared and the protein concentration in the lysates was
determined using the BioRad DC Protein Assay Kit (Cat# 5000112) to ensure equal
loading of proteins per lane. Bands were separated by SDS-PAGE (NuPAGE 4-12%,
Thermo-Fisher Scientific) followed by transfer to polyvinyl difluoride membrane
(Millipore). Membranes were blocked with either 5% dry milk solution or 5% bovine
serum albumin both prepared in TBS-T buffer (20 mM Tris-HCL, pH 7.6, 140 mM NaCl,
0.2% Tween 20) and probed with the following primary antibodies: Rabbit antiLEDGF/p75 (1:1000, Bethyl Laboratories Cat# A300-848A), mouse anti-clusterin alpha
chain (1:1000, Millipore Cat# 05-354), rabbit anti-MDR1/ABCB1 (1:1000 Cell Signaling
Cat# 13342), rabbit anti-DPP4/CD26 (1:3000, Millipore Cat# MABF752), mouse antiNestin (1:1000 Millipore Cat# MAB5326), rabbit anti-DNAJC12 (1:500, Novus Cat#
NBP1-57718), rabbit anti-FABP5 (1:5000; a kind gift from Marino De Leon, Loma
Linda University, Loma Linda, CA), mouse anti-Snail (1:1000, Cell Signaling Cat#
3895S), mouse anti-Twist (1:200, Santa Cruz Cat# sc-81417), rat anti-Vimentin (1:8000,
R&D Systems Cat# MAB2105-SP), rabbit anti-TGM2 (1:1000, Cell Signaling Cat#
3557), rabbit anti-BOP1 (1:1000, Bethyl Cat# A302-148A-M-1), mouse anti-E-cadherin
(1:500, BD Biosciences Cat# 610182), or mouse anti-N-cadherin (1:200, Abcam Cat#
ab12221). The mouse anti-TSPAN8 primary antibody was from Celine Greco and Claude
Boucheix (1:2000) [81].
Following several washes with TBS-T, membranes were incubated with the
appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-mouse
IgG and anti-rabbit IgG, Cell Signaling Cat# 7076 and 7074, respectively; goat anti rat,
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Santa Cruz Cat# sc-2032). HRP-!-actin was utilized as a loading control (Cell Signaling
Cat# 5125). After 2-hour incubation with secondary antibodies, the membranes were
washed several times with TBS-T, and protein bands were detected by enhanced
chemiluminescence (Thermo Fisher Scientific, Cat# 34580). Bands were quantified using
Image J software (National Institutes of Health) and normalized to !-actin control.
Samples were analyzed in at least 3 independent experiments using at least 3 biological
replicates.

Bioinformatics Analysis of Oncomine Cancer Gene Microarray Database
For analysis of mRNA expression of genes of interest in PCa and normal prostate tissues,
we selected 16 datasets from the Oncomine database (Compendia Biosciences; Ann
Arbor, MI; www.oncomine.org). These datasets, derived from gene microarray analyses
of PCa and normal prostate tissues, provide fold-change data for gene expression with P
values calculated by Oncomine using Student’s t-tests. The Grasso dataset included 35
castration-resistant metastatic PCa, 59 localized PCa, and 28 benign prostate tissue
specimens while the Varambally dataset included 6 hormone-refractory metastatic PCa
samples in addition to 7 localized PCa, and 6 normal prostate samples. This allowed us to
compare the transcript expression between these 3 categories of tissues in our genes of
interest.

Tumorsphere Forming Assays
Cells were cultured in 6-well non-tissue culture treated plates at a density of
25,000 cells/ml, and suspended in F12K/RPMI supplemented with 1% knockout serum
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replacement (Fisher Scientific Cat# 10828028), 20 ng/ml human EGF (Millipore Sigma
Cat# E9644), 10 ng/ml human bFGF (PeproTech Cat# 100-18B), 0.1% of albumin
solution 35% in PBS (Sigma Cat# 091M8416), 1% Pen-Strep, 0.1% insulin (Millipore
Sigma Cat# 10516), and 0.1% selenium (Millipore Sigma Cat# 229865). After 24 hours
the floating cells were collected and cultured in separate plates in the medium described
above. Cells were left for 14 days adding or replacing medium as necessary to maintain
growth. Images of cells were taken after at least 14 days post-plating using an Olympus
IX70 microscope with phase contrast and Hoffman modulation contrast and equipped
with a SPOT RT3 imaging system. Using phase contrast 4X images and Image J
software, tumorsphere formation was quantified as percent area in at least four
independent experiments.

Flow Cytometric Analysis of Stem Cell Markers, ALDH Activity, and Cell Death
Adherent PC3-DR and DU145-DR cells were cultured in monolayer to 80-90%
confluency prior to collection for multicolor flow cytometric analysis of putative CSC
markers. Cells were washed with PBS and harvested using a solution containing 0.25%
Trypsin and 2.21mM EDTA (Corning Cat# 25-053-Cl), followed by incubation in fresh
fully supplemented RPMI medium containing 10% FBS for 30 minutes to allow for NCadherin and E-Cadherin recycling following enzymatic cleavage. In parallel,
tumorspheres derived from PC3-DR or DU145-DR cells were collected and dissociated
using 0.25% Trypsin/2.21mM EDTA solution, followed by neutralization with fresh
fully-supplemented medium. Following the 30-minute recovery period, cells were then
labeled with antibodies against CD44, CD24, N-Cadherin, E-Cadherin, or annexin-V for
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15 minutes at room temperature (see Table 5 for antibody specifications). Cells were
washed and resuspended in annexin-V binding buffer (50 mM HEPES, 700 mM NaCl,
12.5 mM CaCl2; pH 7.4) and analyzed immediately on a MACSQuant Analyzer 10
equipped with violet, blue, and red lasers (Miltenyi Biotec). Post-acquisition data analysis
was performed using FlowJo version 10.08.1 (BD).
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Table 5. Antibodies Used for Detection of EMT and CSC Markers by Flow Cytometry.
Antibody

Fluorochrome

CD44

V450

Annexin-V

FITC

CD24

PE

N-Cadherin

PE-Vio770

E-Cadherin

PE-Vio770

Manufacturer Information
BD Biosciences
Cat# 561292
Clone: G44-26
Life Technologies
Cat# V13242
BD Biosciences
Cat# 555428
BD Biosciences
Cat# 56345
Clone: 8C11
Miltenyi Biotec
Cat# 130-099-142
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Laser
Violet

Blue

ALDH activity was detected using Aldefluor assay kit purchased from Stem Cell
Technologies (Cat# 01700) and performed according to manufacturer’s instructions.
Briefly, 2D and 3D cells were prepared and harvested as described above. 400,000 cells
were resuspended in 200 µl of aldefluor buffer and 2 µl of aldefluor reagent to form the
“test” sample (both provided). 200 µl of that text mix were then immediately transferred
to another microcentrifuge tube containing 2 µl of DEAB reagent (provided) to inactivate
the aldefluor reagent and become the “control” sample. Both the control and test sample
were incubated for 45 minutes at 37°C. Samples were then centrifuged and resuspended
in aldefluor buffer to be analyzed immediately on the MACSQuant Analyzer. Postacquisition data analysis was performed using FlowJo version 10.08.1 (BD) with gates
being drawn on the control DEAB+ samples for each cell line 2D and 3D.
Initial gates for intact cells using FSC-A/SSC-A light scatter and doublet
discrimination using FSC-H/FSC-A profiles. Single-stained samples were used to define
compensation matrices. Following compensation, dead cells were excluded based on
annexin-V positivity and only live cells were assessed for putative CSC marker
expression. Gate placements were defined using Fluorescence-Minus-One (FMO)
controls using SSC-A versus marker of interest (Figure 15 for gating strategy and Table 5
for staining strategy for FMO detection). Data are presented as percent of live cells
staining positive for each designated marker and are representative of at least 3
independent experiments.
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Debris Exclusion

Doublet Discrimination

Live Cell Gate

E-Cadherin Gate

N-Cadherin Gate

CD44 Gate

CD24 Gate

Figure 15. Gating Strategy for Multicolor Flow Cytometric Analysis of CSC Markers in
Cells Grown in Adherent (2D) or Non-adherent (3D) Conditions. Following
compensation, gates were set for SSC-A versus marker expression based on
Fluorescence-Minus-One (FMO) controls (inset).
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Table 6. Fluorescence-Minus-One (FMO) Staining Strategy for Detection of CSC
and EMT Markers by flow cytometry
Antibody
Unstained Control
CD44 Only
Annexin-V Only
CD24 Only
N-Cadherin Only
E-Cadherin Only
FMO-CD44
FMO-AV
FMO-CD24
FMO-N-Cadherin
FMO-E-Cadherin
Full Stain

CD44

Annexin-V

CD24

NCadherin

E-Cadherin

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+
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Detection of Cell Viability by Propidium Iodide Staining
PC3 and DU145 cells, DTX-sensitive or -resistant, were seeded in 6-well cluster
plates at 1.25x105 cells per well and allowed to adhere for 24 hours. Separately, PC3-DR
and DU145-DR cells were seeded in non-adherent conditions in 6-well cluster plates at 5
x104 cells per well. Cells were then treated with increasing concentrations of DTX (0.1,
1, 10, 100, 1000 nM) for 72 hours, followed by PI staining using the Dead Cell Apoptosis
Kit for flow cytometry (Life Technologies, Cat# V13242) according to the
manufacturer’s instructions. Briefly, adherent cells were detached from culture using
0.25% Trypsin/2.21mM EDTA solution for 30 seconds, followed by neutralization using
complete RPMI medium containing 10% FBS. Cells grown in non-adherent conditions
were collected from culture medium and dissociated using 0.25% Trypsin/2.21mM
EDTA solution for 30 seconds, followed by neutralization using complete medium
containing 10% FBS. Cells were washed with PBS, suspended in annexin-V binding
buffer and stained with PI (1µg/ mL final concentration) for 15 minutes at room
temperature in the dark, then immediately analyzed on a MACSQuant Analyzer.
Following exclusion of debris and doublet events, single-stained samples were used to
define compensation matrices and experimental gates. Data are presented as percentage
of cells staining negative for PI (percent viability) (see Figure 16 for gating strategy).
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Figure 16. Gating Strategy for Flow Cytometric Analysis of Cell Death. Propidium
iodide (PI) staining was analyzed in DU145 and DU145-DR cells grown in adherent or
non-adherent conditions following 72 hours of exposure to DTX. Gates for PI were set
using unstained controls on pooled samples (right inset).
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Statistical Analysis
Statistical analysis and graph generation was performed using GraphPad Prism
version 6.0c for Mac OSX (GraphPad Software, La Jolla, California USA,
www.graphpad.com). Fold change differences in both qPCR, immunoblotting, Oncomine
data, and tumorsphere percent area were analyzed using Student’s t-test. Results were
considered significant at P < 0.05. One-Way ANOVA was used for the analysis of results
from PI staining experiments comparing percent viability in the resistant 2D (adherent)
compared to resistant 3D (tumorspheres) cultures.
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CHAPTER THREE
SELECTED UNPUBLISHED DATA

LEDGF/p75 May Play a Role in Regulating Inflammatory Cytokines Contributing
to PCa Aggressiveness and Chemoresistance
Lens Epithelial Derived Growth Factor (LEDGF/p75) is an emerging stress
oncoprotein implicated in the transcriptional regulation of survival proteins, contributing
to cancer aggressiveness and chemoresistance [1-6]. Work done in our lab demonstrated
that LEDGF/p75 is upregulated in clinical prostate tumors and contributes to taxaneresistance in PCa cells [7-9]. Furthermore, targeting of this protein with RNA
interference partially resensitizes DTX-resistant cells to docetaxel [10]. The role of
inflammation in PCa initiation and progression has long been established [11], with
inflammatory cytokines such as IL-6 and IL6-R being implicated in PCa aggressiveness,
chemoresistance, and increased serum levels of IL6 in PCa being associated with poor
prognosis [11-14]. In addition, overexpression of LEDGF/p75 has been shown to induce
IL-6 in human keratinocytes. We hypothesize that LEDGF/p75 plays a role in regulating
inflammatory cytokines thereby contributing to PCa aggressiveness and chemoresistance.
To identify inflammatory cytokines regulated by LEDGF/p75 in PCa cells, we
monitored changes in inflammatory gene expression using quantitative real time PCR
pathway specific gene arrays, focusing on the RT2 Profiler Human PCR Inflammatory
Response and Autoimmunity Array (QIAGEN). Transcient knockdown was done on PC3
cells, PC3-DR and DU145-DR cells. RNA was extracted 48-hours post siRNA

101

transfection. RNA was purified, cDNA was made and used to run the inflammatory
arrays comparing each knockdown to the appropriate scrambled control.
LEDGF/p75 knockdown in DTX sensitive PC3 cells was associated with
downregulation of IL-6 and IL-6R transcripts (Figure 17A& B). Consistent with this,
Western blotting analysis showed increased cellular levels of IL-6 and IL-6R in response
to LEDGF/p75 overexpression. These studies were repeated using both DTX-sensitive
and resistant DU145 PCa cells. Our RT-PCR results also indicate that in the context of
chemoresistance, depletion of LEDGF/p75 may play a role in the downregulation of
inflammatory genes such as CCL5, CXCL2, IL-6, NF-kB, TIRAP, and TLR4 (Figure
17B). The most robust gene downregulation in response to LEDGF/p75 depletion in
chemoresistant PCa cells was that of IL-6 (Figure 17B).
To further validate these preliminary results, it was important to use in-house
primers for the determined genes of interest and immunoblotting to demonstrate
upregulation in DTX-resistant cells and downregulation with knockdown of LEDGF/p75.
Preliminary RT-qPCR data demonstrated upregulation of IL-6 in PCR-DR and DU145DR cells (which overexpress endogenous LEDGF/p75) compared to parental PC3 and
DU145 cells (Figure 18A& B). In addition, immunoblotting revealed increased
expression of IL-6R in DTX-resistant and LEDGF/p75-overexpressing PC3 cells, and
increased protein expression of IL-6 in DU145-DR cells (Figure 18C). While the
upregulation of IL-6 protein in the PC3-DR and DU145-DR cells was consistent with the
RT-PCR array results from LEDGF/p75-depleted cells, the IL-6R upregulation observed
in these DTX-resistant cells was in stark contrast with that observed in LEDGF/p75depleted cells (Fig. 17B). Furthermore, we were not able to show by immunoblotting the
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downregulation of IL-6 protein in cells depleted of LEDGF/p75 (data not shown),
suggesting that either LEDGF/p75 does not regulate directly this inflammatory cytokine,
or the IL-6 protein levels in the DR cells are very stable and not totally dependent on
transcript levels.
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A"

B"

C"

Figure 17. Inflammatory Gene Arrays Reveal Possible Target Genes of LEDGF/p75. A.
siRNA-mediated knockdown of LEDGF/p75 in a panel of PCa cell lines. B. RT2 Profiler
RT-PCR inflammatory gene array results showing common candidate gene up- or downregulated in DTX- sensitive and resistant PCa cell lines in response to LEDGF/p75
knockdown. C. The model suggests that when PCa cells transition from chemosensitive
to chemoresistant the stress protein LEDGF/p75 is upregulated and may contribute to the
upregulation of specific inflammatory genes. *Significant (p<0.05) Upregulation in Red
and Downregulation in Blue.
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IL#6R
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Figure 18. Preliminary Validation of Inflammatory Array Results. A. RT-PCR data
showing upregulation of IL-6 in the PC3-DR and DU145-DR PCa cell lines compared to
the parental PC3 and DU145 cells. B. RT-PCR data showing upregulation of IL-6R in the
DTX-resistant PC3 and DU145 PCa cell lines compared to the parental PC3 and DU145
cells. C. Western blot data showing that increased expression of IL-6 and IL-6R protein
correlates with increased LEDGF/p75 expression in PC3-DR, DU145-DR, and
LEDGF/p75 overexpression PCa cell lines compared to parental PCa cells.
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Further development of these preliminary studies will help elucidate mechanisms
by which LEDGF/p75-induced stress and inflammatory genes contribute to
chemotherapy resistance in PCa (Figure 17). The potential role of LEDGF/p75 in coregulating inflammatory cytokines also has important implications for understanding the
role of LEDGF/p75 in healthy individuals and autoimmune disease. This is critical given
recent observations that LEDGF/p75 is the target of autoantibodies in subsets of healthy
individuals and patients with miscellaneous inflammatory or autoimmune conditions
[15].

Migratory Potential of DTX-resistant Cells Compared to DTX-sensitive Cells
The ability for cancer cells to migrate and invade surrounding tissue is an
indicator of their aggressiveness. Using techniques such as migration assays we are able
to determine the effects of a drug or targeting of a gene on a cell line’s migratory
potential. There is inconsistency in the literature on the effects of DTX-resistance on cell
migration. Although DTX-resistant cells are more aggressive and have a mesenchymallike phenotype we observed in scratch/wound assays reduced migration in DTX-resistant
PC3-DR and DU145-DR cells compared to DTX-sensitive PC3 and DU145 cells (Figure
19). As shown in Chapter 2, when PC3 and DU145 cells become resistant to DTX they
upregulate markers of EMT and CSC-like phenotype. As such, they migrate differently as
individual cells, a phenomenon termed single-cell migration, which causes cells to detach
individually and reattach at the center of the scratch/wound, versus migrating as a group
of cells to close the wound [16].
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Figure 19. Representative Scratch-wound!!!!DU145!!!!!!!!DU145DR
Images with Graphs Showing Percent Wound
Recovery. Results show that the DTX-resistant PCa cells (A,! PC3-DR and B, DU145!
DR) have less percent wound recovery
compared to the DTX-sensitive cells (A, PC3 and
B, DU145). Results were statistically significant (p<0.0001).
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Co-targeting LEDGF/p75 and CLU Individually and Together in Combination with
DTX to Resensitize DTX-resistant PCa Cells to Taxane Therapy
Current trends in cancer treatment emphasize combinatorial therapies targeting
multiple redundant, but distinct, cell signaling pathways to more effectively sensitize
cells to standard therapies [17]. Clusterin (CLU) is an anti-apoptotic protein that protects
cells from stressors such as chemotherapy and androgen deprivation. It is upregulated in
several cancers and is well defined as a key contributor to PCa resistance to taxane drugs
[18-21]. Like LEDGF/p75, CLU is highly upregulated in the mCRPC cell lines PC3 and
DU145 after progressive treatment with DTX, leading to induction of chemoresistance
[18, 19, 21]. Downregulation of CLU also results in sensitization to DTX cytotoxicity in
these chemoresistant cells [18]. Thus, LEDGF/p75 and CLU appear to play similar, if not
redundant, roles in promoting taxane resistance in PCa.
Both LEDGF/p75 and CLU are stress survival proteins that are overexpressed in
DTX-resistant PC3 and DU145 cell lines, and promote taxane resistance. Therefore, we
first determined if their expression was interdependent. Western blot analysis showed that
in PC3 cells with stable LEDGF/p75 overexpression, CLU was not overexpressed,
compared to vector control, suggesting that overexpression of CLU in these cells may be
independent of LEDGF/p75 overexpression (Figure 20A). In addition, siRNA-mediated
knockdown of LEDGF/p75 in PC3 cells with ectopic overexpression of LEDGF/p75, and
in DTX-sensitive and –resistant PC3 and DU145 cells did not result in downregulation of
CLU expression (Figure 20B), again supporting the view that CLU expression is
independent of LEDGF/p75 expression.
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Figure 20. Knockdown Studies Reveal that CLU and LEDGF/p75 Expression are
Independent. Both proteins are upregulated in DTX resistant (DR) cells (A) Knockdown
of LEDGF/p75 in DTX-sensitive or resistant cells does not result in downregulation of
CLU (B), whereas knockdown of CLU does not result in consistent downregulation of
LEDGF/p75 (C).
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Western blot analysis of protein lysates from DTX-sensitive and DTX-resistant
PC3 and DU145 cell lines with CLU knockdown showed a slight downregulation of
LEDGF/p75, which was not consistent in all cell lines (Figure 20C). This can be
explained by the fact that CLU knockdown by itself causes apoptotic cell death, leading
to caspase-mediated LEDGF/p75 degradation [22], which could explain the slight
downregulation of this protein observed in Figure 20C.
Given that LEDGF/p75 and CLU exhibit redundant roles in promoting DTX
resistance, through two distinct mechanisms (inhibition of caspase-independent cell death
vs caspase-dependent cell death, respectively) [5, 18, 19], we sought to co-target these
proteins to more effectively re-sensitize chemoresistant PCa cells to taxane therapy. We
performed single or double siRNA-mediated knockdowns of CLU and LEDGF/p75 in the
DTX-resistant PC3-DR and DU145-DR for 48 hours in the presence of 10 nM DTX
(maintenance dose of DTX) and analyzed the morphology of the cells via Hofmann
Modulation Contrast microscopy. As expected, double knockdown of LEDGF/p75 and
CLU resulted in greater cell death than single knockdown of each protein (Figure 21). To
quantify levels of cell death, cell viability was determined by MTT assay up to 96 hours
(Figure 22A& B), and by Annexin/PI staining using flow cytometry (Figure 23A& B).
Using both assays to assess cell viability after single and double knockdown of CLU and
LEDGF/p75 in the presence of DTX, our results showed no difference in cell viability
between the double knockdown and CLU knockdown, suggesting that the effects
observed in the double knockdown are due largely to the effects of silencing CLU.
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Effective in Resensitizing PC3-DR PCa cells to DTX Than Knocking Down Each Protein
Alone. (A) Knockdown was verified by immunoblotting. (B) Double knockdown shows
increased cell death compared to single knockdown of CLU or LEDGF/p75.
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Targeting LEDGF/p75 with SMIs to Resensitize Chemoresistant mCRPC Cells to
DTX Treatment
In addition to its role in cancer, LEDGF/p75 also facilitates HIV-1 integration
into transcriptionally active sites in host chromatin by interacting with the HIV-integrase
(HIV-IN) [23]. Novel small molecule inhibitors (SMIs) targeting the HIV-IN binding
domain (IBD) of LEDGF/p75, located within its C-terminus, have been developed [24]
(Figure 24) .
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Figure 1. A lead molecule with an N-acylhydrazone was identified from a four
feature pharmacophore model mimicking LEDGF/p75 IBD K364, I365, and D366
residues key to viral replication. Representative hydrogen bond donor (HBD) groups
in purple, a hydrophobic (HYD) group in teal, and a negative ionizable group in a
dashed blue circle is shown. New compounds were explored focusing on a central
N-acylhydrazone and two opposite cyclic rings, all components not highlighted as
pharmacophore model-related groups.
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developed pharmacophore models mimicking LEDGF/p75 IBD residues K364, I365, and D366. The Transcriptional$and$
structure of a lead N-acylhydrazone that was identified from the
pharmacophore models and
Stress$Survival$$
inhibited LEDGF/p75-IN interaction inActivities
vitro with an IC50 value below 25 lM is provided in Figure 1. The pharmacophoric mapping of
Protein1Protein$
similar LEDGF/p75-IN inhibitors prompted
an investigation into
interactions
the importance of the central N-acylhydrazone linker. Several lead
molecules containing N-acylhydrazones were then subjected to
substructure and similarity studies which led to the discovery of
new acylhydrazone and hydrazine-based LEDGF/p75-IN inhibitors.
N-Acylhydrazones are known to treat tuberculosis via a mechanism of action targeting the biosynthesis of mycolic acids of the
bacteria cell wall.25,26 Antibacterial salinizide, aconiazide, and
other acylhydrazone prodrugs are hydrolyzed to the active hydrazide component isoniazid (Fig. 2).27,28 N-acylhydrazones have also
been identified to have antiretroviral activity by binding to HIV-1
capsid29 and reverse transcriptase30,31 suggesting potential antiviral activity for this class of LEDGF/p75-IN inhibitors. In this study
we identified acylhydrazones, hydrazines, and diazenes as
LEDGF/p75-IN inhibitors, examined their SAR, and explored strategies to evade cellular metabolism.

Figure 24. Model of LEDGF/p75 Structure Illustrating the IBD Domain. The IBD
domain, a site crucial in transcriptional and stress survival activity and the predicted site
of SMI binding.

2. Results and discussion
2.1. SAR for the inhibition of HIV-1 IN and LEDGF/p75
interaction
2.1.1. Acylhydrazones
Developing small molecule inhibitors that target allosteric
pockets and alternate stages of the viral life cycle is the next step
in a marathon against expanding pools of drug-resistant strains.
We identified N-acylhydrazones as a potential new lead compound
using LEDGF/p75 IBD-based pharmacophore models. The examination of small molecules with a central acylhydrazone evolved from
a series of SAR studies using substructure searches. Further LEDGF/
p75-IN inhibitors were identified from a commercial database (Enamine, Ltd) of half a million compounds and screened using an
amplified luminescent proximity homogeneous assay.32
Structures of select N-acylhydrazones and related compounds
are shown in Figure 3. Compounds 4 and 5 both inhibited
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These SMIs disrupt the LEDGF/p75-HIV-IN interaction, likely by binding to this
C-terminal IBD, which is essential for HIV integration [23]. The transcriptional and
stress survival functions of LEDGF/p75 also depend on the structural and functional
integrity of its C-terminus [1, 22]. Therefore, we hypothesized that repositioning these
HIV-based SMIs is a promising strategy to overcome mCRPC chemoresistance. SMIs
were obtained from Enamine LLC designed by Sanchez, et al [24] DTX-resistant PC3
and DU145 cells were seeded in 96 well plates with and without DTX. 24 hours later
different concentrations (0.1, 1, 10, 100 and 100 nM) of each SMI #14 (Cat# T5756746),
46 (Cat # T5863733), 71(Cat# T5251403), 91(Cat# T5755298), and 118 (Cat#
T05189618) from Enamine LLC (Figure 25A) with and without DTX were added to each
well in triplicates. After 72 hours MTT assay was performed. Preliminary data suggested
that select candidate LEDGF/p75 SMIs #14, 46, 71, and 91 promote selective
chemoresistance to 10 nM DTX in DTX-resistant PC3-DR and DU145-DR cells (Figure
26B& C). Concentration of 10 nM for each SMI is shown because that is where the
change is first noticed and subsequent concentrations were similar (data not shown).
Future studies will require determining the cytotoxic activity of these selected SMIs in
the presence of various concentrations of DTX, establishing that these SMIs bind to
LEDGF/p75, and that they disrupt LEDGF/p75 interactions with other proteins and
transcriptional activity.
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Adherent and Tumorsphere PC3-DR and DU145-DR Cells Upregulate CSC
Markers CD133+ and CD117+
To better define the CSC population in the DTX-resistant cell lines, we performed
flow cytometric analysis using the marker combinations of CD44+/CD24- [25-27], and
CD44+/CD24-/CD133+ or CD44+/CD24-/CD117+ [26, 27]. CD133 expression is
associated with tumor progression, self-renewal capacity, and metastasis colonization and
growth [26]. CD117, also known as c-kit is associated with tumor progression,
metastasis, and resistance to therapy [26]. We observed that PC3-DR cells showed a
statistically significant increase of CD44+/ CD24-/ CD133+ cells. DU145-DR cells also
showed an increase of this subset, although not significant. Both PC3-DR and DU145DR displayed a significant increase of CD44+/ CD24-/ CD117+ cell subpopulations
compared to the parental, drug-sensitive PC3 and DU145 cells (Figure 26).
In addition, we detected increased frequencies of CD44+, CD44+/ CD24- and
CD44+/ CD24-/ CD133+ populations in DU145-DR 3D compared to DU145 3D
tumorspheres (Figure 27A). Although we also observed an increase in the CD44+/CD24/CD117+ population in DU145-DR 3D tumorspheres, this finding did not reach statistical
significance (Figure 27B).
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Figure 26. DTX-resistant mCRPC Cells Upregulate Markers of CSC-like Phenotype
Compared to DTX-sensitive Cells, as Measured by Flow Cytometry. (A) CD44+/ CD24,
CD44+/ CD24-, CD44+/ CD24-/ CD133+, and (B) CD44+/ CD24-/ CD117+. All flow
measurements were acquired from at least 3 independent experiments, *P<0.05,
**P<0.01. Error bars represent mean ± SD.
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Figure 27. DU145 and DU145-DR Tumorsphere Cells Upregulate Markers of CSC-like
Phenotype Compared to DTX-sensitive Cells, as Measured by Flow Cytometry. (A)
CD44+/ CD24-, CD44+/ CD24-, CD44+/ CD24-/ CD133+, and (B) CD44+/ CD24-/
CD117+. All flow measurements were acquired from at least 3 independent experiments,
*P<0.05, **P<0.01. Error bars represent mean ± SD.
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CHAPTER FOUR
OVERALL DISCUSSION
Despite recent advances in the treatment of advanced PCa including Sipuleucel-T,
abiraterone acetate, enzalutamide and CTX [1, 2], resistance to therapy occurs, resulting
in patient death within three years of diagnosis [3-6]. DTX is the current gold standard
for chemotherapeutic treatment of castration resistant tumors. Unfortunately, most
patients receiving DTX experience taxane chemoresistance and disease progression
within seven months of starting treatment [1, 2, 7]. Newer therapeutic agents such as
CTX (also a taxane derivative) have demonstrated some overall survival benefit of
slightly over a year [8]. Therefore, there is an unmet need for new therapeutic drugs used
alone or in combination with current chemotherapeutic agents for the treatment of
mCRPC. The goal of this study was to utilize RNA-seq to define molecular signatures
associated with DTX-resistance in metastatic PCa cells in order to identify novel
therapeutic targets for overcoming this resistance.
Examining the RNA-seq data, we observed that of the 33,118 total genes
examined, 3,754 genes in the DU145-DR cell line had a significant fold change
difference compared to the parental DTX-sensitive DU145 cell line, and 2,552 genes in
the PC3-DR cell line had a significant fold change difference compared to the PC3 cell
line. We chose to focus our studies on the 1,254 genes that were shared or overlapped
between both PC3-DR and DU145-DR cells because these particular differences in gene
expression are common to both DTX- resistant cell lines and likely result from long-term
DTX treatment. GSEA analysis of the RNA-seq data revealed top ranked genes from the
overlap data set, with many of these genes been associated with tumor aggressiveness,
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chemoresistance, or a CSC-like phenotype. We selected some of the top upregulated
genes in the DTX-resistant cells, including DPP4, TSPAN8, DNAJC12, and NES for
validation using qPCR and immunoblotting. In addition, we validated FABP5 and BOP1,
genes associated with PCa aggressiveness.
FABP5 is an intracellular lipid-binding protein that is emerging as a critical
regulator of PCa cell proliferation [9, 10], and targeting FABP5 decreased malignant
progression of CRPC cells in vivo [11]. Recent studies also suggest that FABP5 is a
possible marker for aggressive PCa with FABP5 expression associated with high Gleason
score [12]. Oncomine analysis demonstrates an upregulation of FABP5 expression in
prostate tumors vs. normal, providing further evidence for the role of FABP5 in PCa.
Considering the contribution of FABP5 to an aggressive phenotype in combination with
our results demonstrating a robust transcript and protein fold upregulation in both PC3DR and DU145-DR cells, FABP5 may be a promising target for the treatment of
chemoresistant mCRPC.
BOP1 is an integral component of the ribosomal RNA processing machinery and
a vital component of colorectal tumorigenesis through the promotion of cell migration
and invasion. BOP1’s role in cell migration was demonstrated by the observation that its
loss contributed to a regression of EMT and an increase in E-cadherin expression,
suggesting it may be an upstream inducer of EMT [13, 14]. With our observation of
increased EMT phenotype in the DTX-resistant cell lines, these results suggests that
BOP1 may play a similar role in PCa by contributing to upregulation of EMT in PC3-DR
and DU145-DR cells. In addition, the Oncomine analysis revealed an upregulation of
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BOP1 transcript expression in prostate tumor vs. normal, and BOP1 transcript and protein
expression was upregulated in DTX-resistant cell lines.
DPP4, also known as CD26, is a transmembrane glycoprotein that functions as an
exopeptidase that can inactivate incretins, chemokines, and promotes cell migration
through the upregulation of MMP-9 [15]. DPP4 is upregulated in many cancers including
lung, T-cell lymphomas, thyroid, and prostate [16, 17], and plays a role in a CSC
phenotype in colon cancer [18-20]. In addition, DPP4 contributes to upregulation of
CD44, another CSC marker [15]. Furthermore, CD26+ colon CSCs derived from DTXresistant colon cancer cells were found to form larger and more abundant colonospheres
[18]. Consistent with the RNA-seq data, DPP4 transcript and protein fold expression was
upregulated in the PC3-DR and DU145-DR cells compared to the sensitive PC3 and
DU145 cells. This suggests that DPP4 may be a possible prostate CSC marker that
identifies a chemoresistant phenotype.
TSPAN8, also known as Co-029 and TM4SF3, is a member of the tetraspanin
family consisting of membrane proteins important in direct and indirect communication
between cells by regulating integrins and other cell surface proteins [21]. Also robustly
upregulated in the RNA-seq analysis (sensitive vs. resistant), this protein is positively
correlated with metastasis and worse prognosis in esophageal [22], liver [23], and colon
cancers, where it has been shown to be involved in cell adhesion and motility through a
complex formed with E-cadherin [24]. In addition, TSPAN8 is considered a CSC marker
in pancreatic cancer [25], and whole genome splicing-sensitive microarray analysis in
PCa cells revealed an upregulation of DPP4 and TSPAN8 in DU145 CSC tumorsphere
(3D) population compared to adherent DU145 cells (2D) [26]. This provides evidence
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for the potential role of TSPAN8 and DPP4 upregulation contributing to a CSC
phenotype. As with DPP4, TSPAN8 transcript and protein fold expression was
upregulated in the resistant PC3-DR and DU145-DR cells.
DNAJC12, also known as Hsp40, is a member of the heat shock protein family
and acts as a co-chaperone that can modulate the function of protein complexes. Little is
known about the role of this protein in cancer but it may contribute to tumorigenesis [27,
28]. Oncomine data revealed consistent upregulation of DNAJC12 in PCa versus normal
tissue. We report a possible role of DNAJC12 in PCa chemoresistance by demonstrating
a transcript and protein upregulation of this protein. In addition, the DNAJ family of
proteins have a suggested role as key regulators of CSC function, making them an
attractive target for drug design [29]. DNAJC12 transcript expression has been shown
upregulated in breast cancer stem cells compared to normal cells [30].
NES is a cytoskeletal intermediate filament protein that was first identified as a
marker of neuroepithelial stem/progenitor cells in the brain and is associated with
increasing migration in PCa cells and their expression is induced by androgen deprivation
[31]. In many tumor types, increased NES expression is correlated with high tumor grade
and is suggested to be an indicator of an invasive phenotype in breast, ovarian,
gastrointestinal tumors, and melanoma, where NES is also a predictive marker of poor
response to therapy [32]. NES was also found in PCa cells and tumospheres expressing
stem cell markers including Nanog, Oct4, Sox-2, and CD133, and these tumorspheres
were found to be more chemoresistant [33]. Similar to our studies, NES was also found to
be increased in hepatocellular carcinoma drug resistant cell lines, and was associated with
a mesenchymal phenotype [34]. In breast cancer, NES was found to promote
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proliferation, survival, and migration of breast CSCs by enhancing the Wnt/β-catenin
activation, a mechanism that may be at play in other cancer types [35].
Chemotherapeutics, like DTX, have temporary cytotoxic effects on the bulk
tumor, due to the small population of CSCs with multiple redundant mechanisms that
facilitate cell survival. In addition, the non-proliferative state of CSCs make them cellular
reserves that allows for a small population of cells to persist even after anti-proliferative
treatments and repopulate the tumor or metastasize [36]. With the identification of the
emerging role of CSCs in the acquisition of PCa chemoresistance [6, 36-38], and with the
observation that many highly-ranked genes were associated with a CSC phenotype or
programming, we chose to characterize this population in DTX-resistant PC3-DR and
DU145-DR cells and DTX-sensitive PC3 and DU145 cells to determine if CSC
frequency was increased in the DTX-resistant cells.
CSCs are typically identified based on the presence and/or absence of several cell
surface markers, the combination of which is specific for the CSC-like phenotype
identified in a particular tumor type [32]. The observation that the PC3-DR and DU145DR (2D) adherent cells upregulate CSC markers is consistent with the CSC hypothesis,
where therapy resistance develops in part to a small population of cells that are inherently
resistant and remain dormant during therapy treatment. When the majority of the bulk
tumor is eradicated, this CSC-like population remains and is able to repopulate the area
with cells that are resistant to treatment and upregulate proteins important in pathways
maintaining and promoting metastasis [36]. In addition, the mesenchymal phenotype
displayed by these resistant cells drives this CSC-like phenotype contributing to
aggressive disease progression.
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The link between EMT and CSC is largely unexplored, but recent evidence
suggests that upregulation of EMT proteins and pathways results in a CSC-like
phenotype including self-renewal and therapy resistance [39]. We report here that PC3DR and DU145-DR cells have a higher frequency of cells expressing CSC-like markers,
and higher ALDH+ activity. In addition, the DU145-DR 3D cells formed larger and more
abundant tumorspheres compared to the DTX-sensitive DU145 3D cells, and these
tumorspheres were more resistant to DTX showing increased viability with 10 nM DTX
treatment.
DTX is currently the gold standard treatment for mCRPC and its use ultimately
results in therapy resistance. This important work reveals genes that are upregulated upon
DTX treatment and acquisition of resistance, and that most likely contribute to the
resistance phenotype. Therefore, targeting the pathways involving these genes, including
those responsible for CSC development, in combination with DTX is a promising
strategy to circumventing chemoresistance.

Conclusions and Future Directions
Current targeting of CSCs focuses on the signaling pathways upregulated in stem
cells that are specific to their function. These pathways include Hh, Wnt, Notch, and
NFkB pathways [36], and targeting them has not resulted in any treatments for
chemoresistant patients. This study contributes to the growing body of evidence linking
CSCs to PCa chemoresistance [40, 41] and provides a set of genes for possible targeting
that are implicated in contributing to this CSC phenotype. Many of the other genes highly
ranked by GSEA analysis have roles in cancer and PCa as well as undefined functions,
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suggesting that although CSCs or CSC-associated genes are promising targets for new
treatments, there are many other pathways and mechanisms that are still largely
undefined in this data set, including the role of FABP5 and BOP1 in chemoresistance. It
will also be important to explore the cell type-dependent differences in PC3 and DU145
cells that exist between the resistant phenotypes of these cell lines, evident by the genes
not overlapped or shared between them.
RNA-seq studies provide the framework for research aimed at elucidating new
mechanisms and pathways associated with a DTX-resistant phenotype in order to
discover novel targets for future PCa treatments. Future studies will involve targeting the
top-ranked genes to determine their function in CSC acquisition or DTX-resistance.
Targeting can be done using siRNAs, pharmacological inhibitors, SMIs or antibodies as
is the case with TSPAN8 [42]. Promising candidates will have readily available inhibitors
or validated antibodies that are used in other cancer types. The goal is to show that
inhibition of this protein or pathway associated with the expression of these proteins, will
lead to a disruption in tumorsphere formation, or resensitization of DTX-resistant cells. In
vivo models will be crucial to determining the effect inhibition of these proteins on tumor
volume, metastasis, and/or chemoresistance. Furthermore, future studies should also
focus on validating our RNA-seq data in CSCs derived from PCa patients that developed
taxane resistance. This will help us identify and prioritize more precisely candidate genes
for therapeutic targeting.
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CHAPTER FIVE
METHODOLOGY
The contents described in this chapter are for the purpose of instructing current
and future laboratory members on the key methodologies utilized in this project. This
section will provide key details and nuisances that are crucial to reproduce the
experiments presented in this dissertation. Furthermore, these methods may assist in
troubleshooting common setbacks that may occur when repeating these techniques for
follow-up studies.

Cell Culture
The PC3 and DU145 cell lines used in this study were purchased from ATCC;
please refer to the “ATCC Culture Methods” section on their website for specific
protocols and required growing conditions. These cell lines were also authenticated
through ATCC’s STR profiling service. This authentication step should be done before
any major publication when using a cell line that was purchased a long time ago (no
record remains) or came from another lab. Two additional cell lines were used, PC3-DR
and DU145-DR, which were derived from PC3 and DU145 and passaged in the presence
of docetaxel (DTX) chemotherapy to be drug resistant (DR). The protocol for generation
these DTX-resistant cell lines is in the dissertation of Leslimar Ríos-Colón entitled
“Targeting LEDGF/p75 to Sensitive Chemoresistant Prostate Cancer Cells to Taxanes” in
the “Methodology” chapter. For this study, PC3, PC3-DR, DU145, and DU145-DR cells
were thawed from frozen stocks obtained from the liquid nitrogen storage tank. Each
frozen vial was prepared in freezing medium (Fetal Bovine Serum [FBS] supplemented
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with 10% DMSO) and stored in a box labeled “Du Ross” in the large liquid nitrogen
storage tank. T25 flasks filled with 5 mL of RPMI-1640 cell culture medium were prewarmed in the incubator for at least 10 minutes prior to adding the cells. RPMI-1640 (500
mL) medium consisted of 10% FBS, 100!µl of gentamycin and 1 ml of normocin to
prevent bacterial and fungal contamination. Frozen vials were thawed in the 37°C water
bath (without submerging to prevent contamination), added immediately to pre-warmed
T25 flask with 5 mL of medium, and placed in the incubator. Incubation conditions were
95% air, 5% carbon dioxide, at 37oC. Cells typically attach within 24 hours, at which
point the medium should be changed to remove the DMSO present in the freezing
medium.
Once cells were confluent, which could take between 24-72 hours depending on
the cell density at the time of culture passaging (often referred to as splitting), they were
expanded to a T75 flask. When cells are not confluent enough to passage (80-100%),
medium should be changed every 48-72 hours. Be careful not to split cells at anything
less than 60-70% confluent, since this will result in slower proliferation over time. Also
be careful not to ignore cells for more than 72 hours, since this will result in stress
pathways being upregulated due to serum starvation caused by over confluency and may
alter the “normal” behavior of your cell line. If cells are left too long without splitting,
they may start undergoing cell death so do not use them for experiments and thaw out a
new vial, otherwise you may not get consistent results.
The PC3-DR and DU145-DR cells require the addition of 10 nM DTX to the
medium each time the medium is changed, either during splitting or routine medium
change. 10 mM DTX stocks are kept in the -20°C freezer and one stock is typically kept
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in the freezer located in the cell culture room. Dilution steps are as follows: add 1 µl of
10 mM DTX to 99 µl of RMPI complete medium to make a 100 µM stock and label “A”;
then take 10 µl of A and add to 90 µl of RMPI medium to make a 10 µM stock and label
“B”; finally take 50 µl of B and add to 950 µl of RMPI to make a 500 nM stock and label
“C” . Add 200 µl of C to a T75 flask with 10 mL RPMI media to get the final10 nM DTX
concentration required. Following these dilution steps will lead to more consistent DTX
concentrations versus adding 1 µl of DTX to 1000 µl of RMPI and adding 10 µl of this to
the T75 flask.

Mycoplasma Testing
It is crucial to test cell lines for mycoplasma contamination once thawed or at
least every 6 months and use normocin antibiotics in the medium to prevent
contamination. Some lab members do not use normocin in their medium, so their cells
should be quarantined and kept in a separate incubator away from other cells in the lab.
This is important to ensure that mycoplasma contamination does not occur, which is very
difficult to eliminate. Any contaminated cell lines that cannot be easily acquired again
will need to be treated with normocin for at least 6-8 months to rid of contamination. For
this reason, normocin should be added to the media used for every cell line grown in the
lab. Exceptions should be reviewed by the PI so that appropriate risk assessment can be
made. In addition, cell lines that were not grown in normocin should not be frozen and
used by the general lab, only by the individual working with them. If they are thawed for
distribution to lab members, they need to be tested immediately and grown in medium
containing normocin for maintenance and prevention of contamination. There is currently

137

no evidence that normocin usage will alter cell function or disrupt any selection process,
with the exception of protocols that call for antibiotic-free media. Mycoplasma testing is
done using the MycoAlert PLUS Mycoplasma Detection Kit from Lonza (Cat# LT07701) following manufacturers’ instructions. Normocin is purchased from Invivogen (Cat#
ant-nr-1).

Preparation of Whole Cell Lysates
To collect cells from flasks, medium was aspirated and the walls of the flask were
rinsed with 2-4 mL of sterile PBS. The PBS was aspirated and 1 mL trypsin was added to
the flask, which was placed in the incubator for a few minutes. Note that some cell lines,
especially the parental PC3 and DU145 require more time in trypsin than the DTXresistant cells, which detach from the flask relatively easily. If cells do not appear to be
detaching, a gentle tap from the outside may be enough to detach the cells. Be careful not
to leave trypsin on for too long or tap the flask too vigorously, some cell lines, DU145 in
particular, are sensitive to vigorous tapping and may grow slowly or in clumps as a result.
Cells were collected in 10 ml plastic tissue culture tubes and stored short-term on
ice. Cells were then spun for 4 minutes at 6,000 RPM (centrifuging speed may vary
depending on cell line) in a centrifuge, and the supernatant was discarded. Pellets were
transferred to a 1 ml microcentrifuge tube and washed two times with PBS to remove any
residual trypsin and media. This step is crucial to removing albumin, a highly abundant
protein in cell culture media that may interfere with sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting procedures. The
cell pellet was dissolved in Laemmli sample buffer containing a protease inhibitor
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cocktail (LSB:CPI). The amount of buffer added depended on the size of the pellet. It is
important not to add too much buffer, which could dilute the protein concentration and
make it difficult to load enough protein for immunoblotting. Conversely, adding too little
LSB:CPI may result in adding very small volumes of the sample to wells in the gels,
which may decrease loading consistency. This is because pipetting any volume under 1
µl reduces accuracy. Typically, 150-200 µl of LSB-CPI was added for a pellet derived
from one confluent T75 flask and 30-100 µl for a pellet derived from one confluent well
in a 6-well plate. Lysates may be stored in -80°C at this point, or they may be sonicated
immediately. The lysates were sonicated to ensure proper disruption of cell membranes
and chromatin and passed multiple times through a Hamilton syringe. The lysate was
boiled in the 100°C heat block for 10 minutes. Lysates are stored permanently in the 80°C.

Antibodies
The commercial antibodies used in this study were as follows: Rabbit antiLEDGF/p75 (1:1000, Bethyl Laboratories Cat# A300-848A), mouse anti-Clusterin alpha
chain (1:1000, Millipore Cat# 05-354), rabbit anti-MDR1/ABCB1 (1:1000 Cell Signaling
Cat# 13342), rabbit anti-DPP4/CD26 (1:3000, Millipore Cat# MABF752), mouse antiNestin (1:1000 Millipore Cat# MAB5326), rabbit anti-DNAJC12 (1:500, Novus Cat#
NBP1-57718), rabbit anti-FABP5 (1:5000; a kind gift from Marino De Leon, Loma
Linda University, Loma Linda, CA), mouse anti-Snail (1:1000, Cell Signaling Cat#
3895S), mouse anti-Twist (1:200, Santa Cruz Cat# sc-81417), rat anti-Vimentin (1:8000,
R&D Systems Cat# MAB2105-SP), rabbit anti-TGM2 (1:1000, Cell Signaling Cat#
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3557), rabbit anti-BOP1 (1:1000, Bethyl Cat# A302-148A-M-1), mouse anti-E-cadherin
(1:500, BD Biosciences Cat# 610182), or mouse anti-N-cadherin (1:200, Abcam Cat#
ab12221). The mouse anti-TSPAN8 primary antibody was a kind gift from Celine Greco
and Claude Boucheix (1:2000).

Immunoblotting Procedures
Immunoblotting was performed as follows: equal amounts of protein from whole cell
lysates were loaded into individual wells of 4-12% polyacrylamide gradient gels (SDSPAGE, NuPAGE, Thermo Fisher Scientific). Protein concentrations were determined
utilizing the DC protein assay kit from BioRad following the manufacturers’ instructions.
To compare changes in protein expression, especially slight changes, only 5-10 µg should
be loaded onto wells to avoid saturating the chemiluminescence signal. Typically, 15-20
µg is ideal for most antibodies, but titer or sensitivity of each antibody should be
considered. Proteins were separated by SDS-PAGE and transferred onto polyvinyl
difluoride membranes (PVDF) (Millipore) in a NuPAGE electrophoresis system from
Thermo Fisher Scientific.
Protein sample preparation included 5 µl of NuPAGE LDS sample buffer (4X), 2
µl of NuPAGE reducing agent (10X), and cell lysate. Water was added to make a final
loading volume of 20 µl. Protein separation was done in MOPS-SDS running buffer for
60 minutes at 175 volts. Protein transfer to PVDF membranes was done in diluted 1X
Transfer Buffer (20X Transfer Buffer purchased from Invitrogen) with 100 µl of
antioxidant added. To confirm complete protein transfer, membranes were rocked slowly
at room temperature in Ponceau S stain for 10-20 minutes depending on the protein
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concentration loaded. The membrane was washed gently in double distilled water until
the amount of protein loaded in each well was clearly visible. Images were captured by
cell phone camera, printed, and documented in the lab notebook. Membranes were then
blocked in 5% milk prepared in TBS-T buffer (20 mM Tris-HCL, pH 7.6, 140 mM NaCl,
0.2% Tween 20) for 1-2 hours. Some antibodies required blocking with 5% BSA
prepared in TBS-T. Blocking with either milk or BSA was done at room temperature on
the rocker. All membranes used in these studies were then probed with primary antibody
overnight in the cold room rocker. Not all primary antibodies require overnight
incubation since some antibodies can be exposed to membranes for 2-4 hrs with excellent
results. Thus, each new primary antibody must be optimized for milk vs BSA blocking
buffer, overnight vs 2-4 hr incubation with membranes, appropriate dilution, and cell
line-dependent target protein expression.
If multiple antibodies were used on the same membrane they would either be
added on different days after developing the first one, or the membrane was cut based on
molecular weight regions and each strip individually probed with the corresponding
antibody targeting a protein migrating in a specific region. Alternatively one can probe
the membrane simultaneously with two same species antibodies [rabbit, human, mouse]
recognizing proteins in distant regions of the membrane (e.g 75 kD and 25 kD proteins)
to prevent non-specific interactions or interference caused by mixing different species
antibodies. This however, has never worked well in my experience for the antibodied
used in these studies and resulted in “smeared” and “fuzzy” bands. It is important to note
that the amount of Tween-20 added to the 1X TBS may vary depending on the procedure.
We used 0.2% Tween-20 for every experiment in this study, but other preferred
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concentrations include 0.1-0.15% Tween-20 depending on the antibody. Using too much
Tween-20 may wash away the antibody from the membrane or prevent tight antibody
binding to target protein; using too little, however, may require extensive washing to get
a clean, background-free membrane, which could also result in lower protein signal
detection. For new antibodies, this may also need to be optimized.
Antibody dilution is different depending on the specific antibody and the
expression levels of its target protein in different cell lines or tissue types. When using a
new antibody, it is important to optimize the immunoblotting protocol to determine the
appropriate dilution and protein concentration for each cell line. Following the
manufacturer suggestions typically may not work but these can be used as a starting point
to determine a dilution range for optimizing. When optimizing new antibodies, more
concentrated dilutions (ranging 1:100-1:500) should be tested against increasing protein
concentrations (5-30 ug) to determine optimal concentration. Antibodies should also be
optimized for reactivity in 5% milk or BSA, unless either of these is specifically
recommended in the manufacturer’s product specification sheet..
The membrane with primary antibody was washed three times with TBS-T on the
rocker at room temperature, changing TBS-T every 10 minutes. After this, secondary
HRP-conjugated antibody was added for 1-2 hours depending on the primary antibody
and amount of protein loaded. Membranes were washed as before and enhanced
chemiluminescence (ECL) was used to detect immunoreactivity. ECL was added to
membranes in a wet chamber for 4 minutes, after which the membranes were transferred
to autoradiography cassettes and exposed to autoradiography film for different time
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period to get a range of exposure times that provide an accurate representation of the
immunoreactivity.
Images were quantified using ImageJ software and statistical analysis of protein
fold change, relative to beta-actin or tubulin loading controls, was done using PRSIM
software. It is important to get overexposed and underexposed blots in addition to
moderate exposure because this allows for an accurate interpretation of the strength of the
immunoreactivity. In addition, getting the optimal exposure for both the protein band of
interest and the actin or tubulin becomes crucial when bands are quantified using ImageJ.
Bands that are too overexposed are difficult to quantify accurately since they are out of
the linear signal range (i.e. the chemoluminescent signal is saturated). We used exposure
times that allowed for clear visualization of spaces between adjacent bands in a gel and
that showed undersaturated bands.

RNA Extraction for RNA-sequencing
It is important to ensure that RNA samples to be used for RNAseq studies are of
the highest quality. When working with RNA, it is crucial to clean with ethanol and
RNase Eliminator the workbench and any other surface or object that will come in
contact with the RNA including pipettes, chemical bottles, centrifuge handles, etc. Apply
the RNase eliminator directly to a clean paper towel after using ethanol. Do not add it
directly to a surface or object, it is very dense and forms suds that take a long time to dry.
Total RNA was extracted from prostate cancer cells using the miRNeasy Plus Mini Kit
(Qiagen, Cat# 217004) per manufacturers’ protocol for “Purification of Total RNA from
Animal Cells” found in the miRNeasy Mini Handbook (Qiagen website:
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https://www.qiagen.com/us/resources/resourcedetail?id=632801fb-abc5-4e62-b954ff51f126a34f&lang=en). Chloroform and 100% ethanol are not provided in the kit and
must be purchased separately. Do not use the 190 proof ethanol used for cell culture, it is
important to obtain 100% ethanol and be mindful that if the bottle is opened frequently, it
may not retain the purity necessary for this protocol. Briefly, the protocol encompasses
sample preparation that involved lysing of the cellular membranes, binding of RNA to the
silica filter, washing of contaminants, and elution of pure RNA.
“Step 1b” and “Step 2” from the protocol were utilized for disruption of cells
grown on monolayer. For Step 7, the centrifuge in the cold room was utilized for the 15minute centrifugation and separation. In addition, all optional steps in the protocol to
increase yield were followed (Steps 11 and 14). For Step 16, to increase RNA yield, 30 µl
of RNase-free water was used to elude the RNA into the collection tube twice. This
provided for maximum efficiency of the elution filter. Collected RNA was immediately
put on ice in a clearly labeled tube and given to the LLU Genomics core for storage in
their -80 freezer prior to RNA sequencing.

RNA Extraction for Quantitative Real-Time PCR
As with RNA extraction for RNAseq samples, the workspace must be cleaned
thoroughly with ethanol and RNase Eliminator. Total RNA was extracted using the
RNeasy Plus Mini Kit (Qiagen, Cat# 74134) per manufacturers’ instructions for
“Extraction from Animal cells” (Qiagen website:
https://www.qiagen.com/us/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbcbf9f6fa33e24&lang=en). Briefly, cell samples are first lysed and then homogenized as
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indicated in the instructions, adding ethanol to provide ideal RNA binding conditions.
Lysates are then loaded into the RNeasy Mini spin column where RNA binds to the silica
membrane and all contaminants are washed away using the buffers provided in the kit.
Pure, concentrated RNA is eluded in RNase-free water (provided).
The first step requires RNAprotect Cell Reagent that can be purchased separately.
For a T75 flask, 1 ml or RNAprotect was added, and for one well in a 6-well plate 500 µl
were added. For homogenizing the lysate, “Step 5b” was done using a 1 mL syringe and a
25-gauge needle. As with the miRNeasy kit, all optional steps were followed. For “Step
14”, 30 µl of RNase-free water were used to elude the RNA into the collection tube
twice. Before starting the procedure, 70% ethanol must be prepared and RLTPlus (2 mL)
must be made using the RLT buffer provided and the beta mercaptoethanol (20 µL)
stored in the 4°C fridge. Be sure to inspect the kit before use, and add the necessary
components to each buffer. The lids of each bottle will specify what must be added and
will allow for a check mark to be written if this step was done previously.
After extraction, RNA was quantified using the NanoDrop spectrophotometer. Be
sure to look for A260/280 ratios of around 2.0, indicating that the sample is pure RNA. A
low A260/280 ratio (below 1.8) is indicative of contamination with phenol, TRIzol, or
other aromatic compounds that are used in the extraction process and may appear in the
sample if the washing steps were not complete. Thus, the A260/280 ratio should always
be as close to 2.0 for RNA, and around 1.8 for “pure” DNA.

Quantitative Real-Time PCR
The iScript cDNA synthesis kit (BioRad, Cat# 1708891) was used to reverse
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transcribe RNA (0.5µg) into cDNA following manufacturers’ instructions. Use the
concentration determined by the NanoDrop to calculate the RNA concentration required.
Briefly, buffer mix was prepared for all reactions, adding in the following order (per
reaction): 4 µl iScript Reaction Mix, 0.5 µg RNA template, 1 µl iScript Reverse
transcriptase, and nuclease-free water to attain a final volume of 20 µl. Reaction was
mixed thoroughly by pipetting up and down and added to a 96-well qPCR plate. The
plate was sealed with adhesive film and placed in the thermal cycler with the following
conditions: 5 mins at 25°C, 20 mins at 46°C, 1 min at 95°C, and hold at 4°C. cDNA is
very stable and can be stored in the -20 freezer. In addition, from this point on, ethanol is
sufficient for cleaning the workspace.
qPCR was done using the MyiQ real-time PCR detection system using iQ SYBR
Green Supermix (BioRad, Cat# 1708882) following the manufacturer’s directions.
Primer sequences are listed in Chapter 2, Table 4. Primers were commercially
synthesized by Integrated DNA Technologies (IDT) and prepared adding 8 µl of the
reverse and forward primers in 64 µl of nuclease-free water. For one reaction, 12.5 µl of
SYBR green master mix, 1 µl of primer mix, and 10.5 µl of nuclease-free water were
added together and placed on ice. Then, 1 µl of cDNA was added to the 96-well qPCR
plate and 24 µl of the reaction mix was added to the corresponding well. Each primer had
a different reaction mix. The cycling conditions were 95°C for 15 min, 95°C for 15s,
60°C for 60s for 35 cycles, followed by melt analysis from 60 to 95°C. Expression levels
were normalized to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Samples were analyzed in at least four independent biological replicates
performed in triplicates. Depending on the cell lines used and treatments being compared,
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it may be necessary to optimize housekeeping genes since certain treatments may cause
changes in transcript expression. For example, treating cells with dexamethasone or DTX
may alter !-actin mRNA expression in some cell lines. Ensuring stable housekeeping
gene expression between the control and test sample is crucial to getting reliable mRNA
fold changes.

Tumorsphere Forming Assays
PC3, PC3-DR, DU145, and DU145-DR cells were cultured in 6-well non-tissue
culture treated plates at a density of 25,000 cells/ml, and suspended in F12K/RPMI
medium supplemented with 1% knockout serum replacement (Fisher Scientific Cat#
10828028), 20 ng/ml human EGF (Millipore Sigma Cat# E9644), 10 ng/ml human bFGF
(PeproTech Cat# 100-18B), 0.1% of albumin solution (35% in PBS) (Sigma Cat#
091M8416), 1% Pen-Strep, 0.1% insulin (Millipore Sigma Cat# 10516), and 0.1%
selenium (Millipore Sigma Cat# 229865). 50 mL of F12K medium (500 mL bottle) and
50 mL of RPMI medium (500 mL bottle) were removed inside the sterile hood and the
EGF, FGF, and insulin were added outside the hood and filtered with a 10 mL syringe
filter and added to the sterile media bottles. After 24 hours, the medium along with the
floating cells were re-plated into a new 6-well non-tissue culture treated plate to remove
any attached cells. Cells were left for 14 days and medium was added as needed. To
visualize tumorsphere formation, images of cells were taken after 14 days post-plating
using an Olympus 1X70 Microscope with phase contrast and Hofmann Modulation
Contrast (HMC), equipped with a SPOT RT3 imaging system. Images were taken of
multiple fields using 4X objective for quantification of % tumorsphere by area.
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Flow Cytometric Analysis of Stem Cell Markers, ALDH activity, and Cell Death
Adherent PC3, PC3-DR, DU145, and DU145-DR cells were cultured in
monolayer as previously described. Cells were washed with PBS and harvested using
trypsin, followed by incubation in fresh fully supplemented complete RPMI medium for
30 minutes to allow for N-Cadherin and E-Cadherin recycling following enzymatic
cleavage. Tumorspheres derived from PC3-DR and DU145-DR cells were collected in a
15 ml tube and dissociated using 500 µl-1000 µl of trypsin pipetting up and down
vigorously for 2-5 minutes. Complete RPMI medium was added to the tube for recovery.
After a 30-minute recovery period, 1.0x 105 cells were plated in a 96 well plate
skipping every other well on each side and labeled with antibodies against CD44 (BD
Biosciences, Cat# 561292), CD24 (BD Biosciences, Cat# V13242), CD133 (Miltenyi,
Cat# 130-098-142), CD117 (Miltenyi, Cat# 130-099-327), N-Cadherin (BD Biosciences,
Cat# 555428), E-Cadherin (Miltenyi Biotec, Cat# 130-099-129) or annexin-V for 15
minutes at room temperature. Cells were washed and resuspended in annexin binding
buffer and analyzed immediate on the MACSQuant Analyzer 10 equipped with violet,
blue, and red lasers (Miltenyi Biotec). Post-acquisition data analysis was performed using
FlowJo version 10.08.1 (BD).
Data analysis started with gating for intact cells by comparing forward scatter
(FSC-A) to side scatter (SSC-A) and then doublet discrimination using FSC-H/FSC-A
profiles. Doublet discrimination is important because it ensures that only single cells are
counted and not two cells clumped together with an artificially enhanced signal. Singlestained samples were used to compensate negative matrices. Dead cells were then
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compensated based on annexin-V positivity and only live cells were assessed for putative
CSC marker expression.
ALDH+ activity was detected using an Aldefluor assay kit purchased from Stem
Cell Technologies (Cat# 01700) following manufacturer’s instructions. 2D (monolayer)
and 3D (tumorsphere) cells were prepared and harvested as described above in a
microcentriguge tube. 4.0x105 cells were resuspended in 200 µl of aldefluor buffer
(provided by the kit) and 2 µl of aldefluor reagent (provided) were added to form the
“test” sample. 200 µl of the text mix were then immediately transferred to another
microcentrifuge tube containing 2 µl of DEAB reagent (provided) to inactivate the
aldefluor reagent and become the “control” sample. To get an accurate control reagent it
is important to transfer the 200 µl to the DEAB reagent after less than 5-10 seconds
because this stops the reaction and allows for an accurate baseline control. Both the
control and test sample were incubated for 45 minutes at 37°C (in CO2 incubator).
Samples were then centrifuged and resuspended in aldefluor buffer into round bottom
glass cuvettes to be analyzed immediately on the MACSQuant Analyzer. Data analysis
was done on FlowJo version 10.08 (BD) with gates drawn on the control DEAB+
samples for the negative gate and the positive gate was drawn on the sample predicted to
have the most ALDH+ activity (PC3-DR, DU145-DR). This means that each cell line
tested will have a different positive and negative gate.
Running the MACSQuant requires training and guidance from the Flow
Cytometry Core, managed by Dr. Kimberly Payne’s Laboratory. Before using the
machine be sure to get help from a lab member that has extensive experience running it to
ensure it is set up properly and cleaned before and after use. The antibodies used in this
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experiment were previously titrated by running a pilot with various concentraions (low
and high) of antibody to determine which dilution falls witin the voltage range.
Therefore, it is not necessary to adjust the voltage of the antibody channels. It is
necessary, however, to adjust the voltage for SSC/FSC to ensure that the cells are within
the view screen. This is crucial for accurate analysis and is done using the Unstained
sample. For ALDH analysis, it is necessary to adjust the voltage of the aldefluor gate
using the control and test sample with the highest predicted ALDH+ activity to ensure
that the cells appear within the view screen window.

Detection of Cell Viability by Propidium Iodide staining
PC3, DU145, PC3-DR, and DU145-DR cells were seeded in 6-well plates at
1.25x105 cells per well and allowed to adhere for 24 hours. Separately, PC3-DR and
DU145-DR cells were seeded in non-adherent conditions in 6-well plates at 5 x104 cells
per well and treated with 10 nM DTX for 72 hours, followed by PI staining using the
Dead Cell Apoptosis Kit for flow cytometry (Life Technologies, Cat# V13242). Adherent
cells were detached from culture flasks or dishes using trypsin for 30 seconds, followed
by neutralization using complete RPMI medium containing 10% FBS. Cells grown in
non-adherent conditions were collected from culture medium and dissociated also using
trypsin. Cells were washed with PBS, suspended in annexin-V binding buffer and stained
with propidium iodide (PI) (1µg/ mL final concentration) for 15 minutes at room
temperature in the dark, then immediately analyzed on a MACSQuant Analyzer. Analysis
included identification of intact cells (exclusion of debris), doublet discrimination, and
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compensation using single stained cells for negative and positive gates. Data is then
presented as cells staining negative for PI (percent viability).

Cell Migration Assay
To evaluate migratory potential/response of PC3 and DU145 compared to their
chemoresistant counterparts a scratch wound-healing assay was performed. Cells were
seeded and grown to 100% confluency in 6-well plates in complete RPMI medium (with
DTX added for the resistant cell lines). Three wound areas were generated per well by
scratching three lines across the confluent monolayer cell surface with a 200 µl pipette
tip. Be careful not to scratch too hard since this may damage the surface of the flask,
preventing cells from migrating into the wound. Images of the wound areas were taken at
0, 24, and 48 hours using the Olympus 1X70 inverted microscope equipped with SPOT
RT3 Imaging System using a 4X phase contrast or HMC objective. To determine the
exact spot where the 0-hour image was taken for the subsequent time points, a circle was
drawn on the plate lid. Percent wound recovery was determined using Image J software
measuring 6 randomly drawn lines across the wound at each time point used.

MTT Viability Assay
PCa cells were seeded in 96-well plates at densities of 5x104 or 8x104 cells per
well and allowed to grow for 24 hours. Cells were then treated with and without 10 nM
DTX (in triplicates) in the presence or absence of LEDGF/p75 small molecule inhibitors
(SMIs) for 48, 72 and 96 hours. In other experiments, single or double knockdowns of
LEDGF/p75 or CLU were performed in PCa cells as described in Chapter 3. Cell
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morphology was visualized in control and treated cells using the inverted Olympus IX70
microscope equipped with HMC and imaging system.
To assess cell viability, a modified 3-(4,5-dimethylthiazol- 2-yl)-2,5diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma-Aldrich) was performed.
This assay indirectly measures the activity of NAD(P)H dehydrogenases, which reduce
the yellow MTT substrate into its insoluble formazan, which has a purple/dark blue color
in viable cells. The activity of these dehydrogenases often correlates with cell viability
and decreases during cell death. It can be also slowed down in cells that are not rapidly
proliferating or are metabolically compromised, which could be wrongly interpreted as
cell death. The MTT substrate was prepared in dPBS (1 mg/1 mL) and 25 µl was added
to each well and placed in the incubator. After a max 2-hour incubation, the plate was
spun down (to collect and accurately count all floating cells, which are typically derived
from mitotic or dead cells). This centrifugation step is critical when treating cells with
DTX and other taxane drugs, which arrest cells in mitosis leading to their detachment
from the bottom surface of the plates without causing immediate death. After
centrifugation the MTT/medium supernatant was pipetted off the wells (do not aspirate),
150 µl of DMSO were then added to each well, and the plate was placed on the shaker to
dissolve the crystals into a colored solution. Absorbance of this solution was measured at
460 and 490 nm using a spectrophotometer. Values were normalized to the absorbance
obtained for the untreated control cells. Given that the MTT reagent is light sensitive
most of the steps were conducted in the dark.
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Statistical Analysis
GraphPad Prism 6 was used for statistical analysis for these studies. Differences
between each group (expression, viability, etc.) were analyzed using unpaired Student’s ttest. ANOVA was utilized when comparing multiple groups and P values below 0.05
were considered statistically significant (*P < 0.05; ** P < 0.01; ***P < 0.001).

Final Remarks
Additional protocols for experiments not shown in this dissertation, and specific
details pertaining to each experiment can be found in the Christina Cajigas-Du Ross’
laboratory notebooks and electronic files stored in the Casiano Laboratory at Loma Linda
University Center for Health Disparities and Molecular Medicine (Mortensen Hall rooms
102-103).
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